 
   
 i 
 
IRB Protocol #: 19 -04020045  
IND #: [ZIP_CODE]  
[STUDY_ID_REMOVED]  
PROTOCOL  
 
 
 
 
 
 
 
 
A randomized, placebo -controlled clinical trial examining the 
efficacy of Fecal Microbiota Transplantation (FMT) and 
subsequent dietary fiber in patients with moderate ulcerative 
Colitis   
 
 
 
 
 
Version Date: 11/13/2024  
 
 
 
 
 
 
 
 
 
Principal Investigator:  
[INVESTIGATOR_704528], MD PhD  
Jill Roberts Center for IBD  
[ADDRESS_957327], 9th Flr  
[LOCATION_001], NY [ZIP_CODE]  
P. ([PHONE_14689]  
E. [EMAIL_13476]  
IRB Protocol #: 19-04020045  Version Date:  11/13/2024    
ii 
 Co-Investigators:      
 Carl Crawford, MD   Ellen Scherl, MD  
 The Division of Gastroenterology & Hepatology   Jill Roberts Center for IBD 
 [ADDRESS_957328], 9th Fl r 
 [LOCATION_001], NY [ZIP_CODE]   [LOCATION_001], NY [ZIP_CODE]  
 P. (646) -962-4000   P. (212) -746-5077  
 E. [EMAIL_13477]   E. [EMAIL_13478]  
   
 Dana Lukin, MD PhD   Rachel Niec, MD PhD  
 Jill Roberts Center for IBD   Jill Roberts Center for IBD  
 [ADDRESS_957329], 9th Flr 
 [LOCATION_001], NY [ZIP_CODE]   [LOCATION_001], NY [ZIP_CODE]  
 P. (212) -746-5077   P. (212) -746-5077  
E. [EMAIL_13479]   E. [EMAIL_13480]   
     
Statistician:    Clinical Nutritionist : 
 Paul J. Christos, DrPH , MS   Ryan Warren,  MS, RDN, CDN  
 Department of Biostatistics and Epi[INVESTIGATOR_704529] 
 [ADDRESS_957330], 9th Flr  
 [LOCATION_001] NY [ZIP_CODE]   [LOCATION_001], NY [ZIP_CODE]  
 P. [PHONE_14690]   P: [PHONE_14691]  
 F: 646 -962-0281   E. [EMAIL_13481]  
 E. [EMAIL_1071]    
 
Study Coordinator s:    
 Nancy Tran   Alexa Lavergne  
 Jill Roberts Center for IBD  Jill Roberts Center for IBD  
 [ADDRESS_957331], 9th Flr   
 [LOCATION_001], NY [ZIP_CODE]   [LOCATION_001], NY [ZIP_CODE]  
 P. (646) -697-0985   P. (646) -697-0985   
 E. [EMAIL_13482]   E. [EMAIL_13483]   
 
 Benjamin Pundyk  
 Jill Roberts Center for IBD  
 [ADDRESS_957332], 9th Flr 
 [LOCATION_001], NY [ZIP_CODE]  
 P. (646) -697-0985  
 E. [EMAIL_13484]  
    
Participating Sites:   
  Study  Enrollment and Treatment                                    Sample Processing and Data Analysis                        
 The Jill Roberts Center for IBD  The Jill Roberts Institute for Research in IBD  
 Gastroenterology and Hepatology at DHK  Belfer Research Building, 7th Flr 
 Weill Cornell Medical Center  / NYP Hospi[INVESTIGATOR_307]  [ADDRESS_957333], 9th Fl r [LOCATION_001], NY [ZIP_CODE]  
 [LOCATION_001], NY [ZIP_CODE]    
IRB Protocol #: 19-04020045  Version Date:  11/13/[ADDRESS_957334] OF ABBREVIATIONS  ................................ ................................ ................................ ...... IX 
1. PROTOCOL SUMMARY  ................................ ................................ ................................ .......  1 
1.1 Study Schematic  ................................ ................................ ................................ .........  3 
1.2 Study Objectives  ................................ ................................ ................................ ........  4 
1.2.1  Primary Objective  ................................ ................................ ................................  4 
1.2.2  Secondary Objective(s)  ................................ ................................ ........................  4 
1.2.3  Exploratory Objective(s)  ................................ ................................ ......................  4 
2. BACKGROUND  ................................ ................................ ................................ ...................  4 
2.1 Ulcerative Colitis  ................................ ................................ ................................ ........  4 
2.2 Fecal Microbiota Transplant (FMT)  ................................ ................................ .............  5 
2.3 Dietary Fiber Supplementation  ................................ ................................ ...................  6 
2.4 Rationale  ................................ ................................ ................................ ...................  7 
2.4.1  FMP Lower Delivery Microbiota Transplant (FMP250)  ................................ ..........  7 
2.4.2  Psyllium Husk Powder  ................................ ................................ .........................  7 
2.5  Risk/Benefit Assessment  ................................ ................................ ...........................  8 
2.5.1  Known Potential Risks  ................................ ................................ .........................  8 
[IP_ADDRESS].  FMT -related : (adapted from OpenBiome FMP250 Investigator Brochure):  ...........  8 
[IP_ADDRESS].  Psyllium -related  ................................ ................................ ................................ .. 9 
2.5.2  Known Potential Benefits  ................................ ................................ ....................  9 
[IP_ADDRESS].  FMT -related  ................................ ................................ ................................ ........  9 
[IP_ADDRESS].  Psyllium -related  ................................ ................................ ................................ .. [ADDRESS_957335] SELECTION  ................................ ................................ ................................ .........  12 
4.1 Study Population ................................ ................................ ................................ ...... 12 
4.2 Inclusion Criteria  ................................ ................................ ................................ ...... 12 
4.3 Exclusion Criteria  ................................ ................................ ................................ ..... 14 
4.4 Lifestyle Considerations  ................................ ................................ ...........................  14 
4.5 Screen Failures  ................................ ................................ ................................ .........  14 
4.6 Strategies for Recruitment and Retention  ................................ ................................ . 14 
IRB Protocol #: 19-04020045  Version Date:  11/13/[ADDRESS_957336] Registration (WCM only)  ................................ ................................ ..............  [ADDRESS_957337] Registration (Sub -sites)  ................................ ................................ ....................  15 
6. STUDY PROCEDURES  ................................ ................................ ................................ ........  15 
6.1 Schedule of Assessments  ................................ ................................ ..........................  15 
6.1.1  Screening Visit (Days -28 to -3) ................................ ................................ ..........  17 
6.1.2  Treatment Phase  ................................ ................................ ...............................  18 
[IP_ADDRESS]  Screening Colonoscopy (Baseline, Week 0 Day 0)  ................................ ............  18 
[IP_ADDRESS]  Clinic Visit 3 (Week 8 ± 5 day(s))  ................................ ................................ ..... 19 
6.1.3  Follow -up Phase  ................................ ................................ ................................  19 
[IP_ADDRESS]  Phone Consults  ................................ ................................ ..............................  19 
[IP_ADDRESS]  Clinic Visits ................................ ................................ ................................ ..... 19 
6.1.4  COVID -19 Study Modifications  ................................ ................................ ...........  19 
7. STUDY INTERVENTION  ................................ ................................ ................................ ..... 20 
7.1 Study Intervention/Device Description  ................................ ................................ ..... [ADDRESS_957338] Preparation  ................................ ................................ ................................ . 23 
7.8 Dosing and Administration  ................................ ................................ .......................  24 
7.8.1  FMP250  ................................ ................................ ................................ ................  24 
7.8.2  Psyllium  ................................ ................................ ................................ ................  24 
7.8.3  Dosing Delays/Dose Modifications ................................ ................................ ..... 24 
7.9 General Concomitant Medication and Supportive Care Guidelines  ............................  24 
7.10 Duration of Therapy and Criteria for Removal from Study  ................................ ...........  24 
7.11 Duration  of Follow Up  ................................ ................................ ................................  25 
7.12 Measures to Minimize Bias: Randomization and Blinding  ................................ ............  25 
7.13 Study Intervention/Follow -up Compliance  ................................ ................................ .. 26 
8. STUDY INTERVENTION DISCONTINUATION AND PARTICIPANT 
DISCONTINUATION/WITHDRAWAL  ................................ ................................ ......................  26 
8.1 Discontinuation of Study Intervention  ................................ ................................ ...... 26 
8.2 Participant Discontinuation/Withdrawal from the Study  ................................ ..........  27 
IRB Protocol #: 19-04020045  Version Date:  11/13/[ADDRESS_957339] to Follow Up  ................................ ................................ ................................ ..... 27 
9. CORRELATIVE/SPECIAL STUDIES  ................................ ................................ .......................  28 
9.1 Laboratory Correlative Studies  ................................ ................................ .................  28 
9.1.1  Microbiome – Laboratory Correlative Study #1  ................................ ..................  28 
[IP_ADDRESS]  Collection of Specimen(s):  Fecal  ................................ ................................ ..... 28 
[IP_ADDRESS]  Handling of Specimen(s): Frozen -80C ................................ .............................  28 
9.1.2  Lamina propria cells – Laboratory Correlative Study #2  ................................ ...... 28 
[IP_ADDRESS]  Collection of Specimen(s):  Biopsy  ................................ ................................ .. 28 
[IP_ADDRESS]  Handling of Specimen(s): Collected in PBS, Processed in Longman lab  .............  28 
9.1.3  Peripheral Blood – Laboratory Correlative Study #3  ................................ ...........  28 
[IP_ADDRESS]  Collection of Specimen(s):  Blood sample  ................................ .......................  28 
[IP_ADDRESS]  Handling of Specimen(s): Processed in Longman lab  ................................ .......  28 
9.2 Special Studies  ................................ ................................ ................................ .........  28 
9.2.1  Special Correlative Study #1  ................................ ................................ ..............  28 
[IP_ADDRESS]  Assessment  ................................ ................................ ................................ .... 28 
9.2.2  Special Correlative Study #2  ................................ ................................ ..............  28 
[IP_ADDRESS]  Assessment  ................................ ................................ ................................ .... [ADDRESS_957340]  ................................ ................................ ............................  29 
10.1 Response Criteria  ................................ ................................ ................................ .......  29 
10.1.1 Primary Endpoint Assessments  ................................ ................................ ................  29 
[IP_ADDRESS] Mayo Scoring System30 ................................ ................................ .........................  29 
10.1.2 Secondary Endpoint Assessments  ................................ ................................ ............  30 
[IP_ADDRESS] Biomarkers  ................................ ................................ ................................ ...........  30 
[IP_ADDRESS] Adverse Event Reporting  ................................ ................................ .......................  30 
10.2 Duration of Response  ................................ ................................ ................................ . 30 
10.3 Progression -Free Survival  ................................ ................................ ...........................  30 
10.4 Other Response Parameters  ................................ ................................ .......................  30 
11. DATA REPORTING / REGULATORY CONSIDERATIONS  ................................ ......................  [ADDRESS_957341]/Ethics Committee Approval  ................................ ........  [ADDRESS_957342] Retention  ................................ ................................ ................................ . 32 
12.1 Sample Size and Analysis Plan  ................................ ................................ .....................  33 
12.2 Sample Size/Accrual Rate  ................................ ................................ ...........................  34 
12.3 Stratification Factors  ................................ ................................ ................................ .. 34 
12.4 Analysis of Endpoints  ................................ ................................ ................................ .. 34 
12.4.1  Analysis of Primary Endpoints  ................................ ................................ ........  34 
IRB Protocol #: 19-04020045  Version Date:  11/13/2024    
vi 
 12.4.2  Analysis of Secondary Endpoints  ................................ ................................ .... 34 
12.4.3  Analysis of Exploratory Endpoints  ................................ ................................ .. 34 
12.5 Interim Analysis  ................................ ................................ ................................ ..........  35 
12.6 Reporting and Exclusions  ................................ ................................ ............................  35 
12.6.1  Evaluation of Toxicity  ................................ ................................ .....................  35 
12.6.2  Evaluation of Response  ................................ ................................ ..................  35 
13. ADVERSE EVENT REPORTING REQUIREMENTS  ................................ ................................  35 
13.1 Adverse Event Definition  ................................ ................................ ............................  35 
13.1.1  Investigational Drug, FMP250, Risks (Potential Adverse Events)  ......................  36 
13.1.2  FMT Procedural Risks (Potential Adverse Events) ................................ ............  38 
13.1.3  Risk from colonoscopy and sigmoidoscopy (Potential Adverse Events)  ............  [ADDRESS_957343] Review (Potential Adverse Events)  .........................  38 
13.1.5  Risk from Blood Draws (Potential Adverse Events) ................................ ..........  38 
13.1.6  Risk from Placebo (Potential Adverse Events)  ................................ .................  39 
13.1.7  Risk from Psyllium Husk (Potential Adverse Events)  ................................ ........  39 
13.1.8  Risk from Anti -Diarrheal Agents (Potential Adverse Events)  ............................  39 
13.1.9  Risk for Women of Child -Bearing Potential  ................................ .....................  39 
13.1.10  Likelihood of Any Adverse Event  ................................ ................................ .... 40 
13.1.11  Adverse Event Characteristics and Related Attributions  ................................ .. 40 
13.1.12  Recording of Adverse Events  ................................ ................................ ..........  41 
13.1.13  Reporting of AE to WCM IRB  ................................ ................................ ..........  41 
13.1.14 Reporting of AE to FDA  ................................ ................................ .......................  41 
13.1.15  Reporting Events to Participants  ................................ ................................ .... 41 
13.1.16  Reporting of Pregnancy  ................................ ................................ ..................  41 
13.2 Definition of SAE  ................................ ................................ ................................ ........  42 
13.2.1  Reporting of SAE to IRB  ................................ ................................ ..................  42 
13.2.2  Reporting of SAE to FDA [For Protocols Where WCMC is the Sponsor -
Investigator]  ................................ ................................ ................................ ..................  42 
13.2.3  Reporting of SAE to OpenBiome  ................................ ................................ ..... 43 
13.3 AE/SAE Follow Up  ................................ ................................ ................................ .......  43 
13.4 Time Period and Frequency for Event Assessment  ................................ .......................  43 
13.4.1. AE/SAE Monitoring  ................................ ................................ .............................  43 
13.4.2. AE/SAE Assessment  ................................ ................................ ............................  46 
[IP_ADDRESS] Assessment of Severity ................................ ................................ ......................  46 
[IP_ADDRESS] Assessment of Causality  ................................ ................................ ....................  46 
14. UNANTICIPATED PROBLEMS INVOLVING RISKS TO SUBJECTS OR OTHERS ........................  47 
14.1 Definition of Unanticipated Problems Involving Risks to Subjects or Others (UPI[INVESTIGATOR_14845])  47 
14.1.2  Unanticipated Problem Reporting  ................................ ................................ .. 48 
15. DATA AND SAFETY MONITORING PLAN (DSMP)  ................................ ..............................  48 
15.1. Plan for informed consent compliance  ................................ ................................ .......  49 
15.2. Plan for HIPAA compliance  ................................ ................................ ........................  49 
IRB Protocol #: 19-04020045  Version Date:  11/13/2024    
vii 
 15.3. Annual Reporting  ................................ ................................ ................................ ...... 49 
15.4. Halting Rules  ................................ ................................ ................................ .............  50 
References  ................................ ................................ ................................ .........................  51 
 
 
 
  
IRB Protocol #: 19-04020045  Version Date:  11/13/2024    
viii 
 Statement of Compliance  
 
The trial will be conducted in accordance with International Conference on Harmonization  Good Clinical 
Practice (ICH GCP), applicable [LOCATION_002] (US) Code of Federal Regulations (CFR), and the Weill Cornell 
Medical College  Terms  and Conditions of Award. The Principal Investigator [INVESTIGATOR_38024], or changes to the protocol will take place without prior agreement from the Investigational New Drug 
(IND) or Investigational Device Exemption (IDE) sponsor, funding a gency and documented appr oval from 
the Institutional Review Board (IRB), except where necessary to eliminate an immediate hazard(s) to the 
trial participants. All personnel involved in the conduct of this study have completed Human Subjects 
Protection and ICH GCP Training.  
 
The protocol, informed consent form(s), recruitment materials, and all participant materials will be 
submitted to the IRB for review and approval.  Approval of both the protocol and the consent form must 
be obtained before any participant is enrolled.  Any  amendment to the protocol will require review and 
approval by [CONTACT_3484].  All changes to the consent form will 
be IRB approved; a determination will be made regarding whether a new consent needs to be obtained  
from participants who provided consent, using a pr eviously approved consent form.  
 
 
Confidentiality Statement  
 
This document is confidential and is to be distributed for review only to investigators, potential 
investigators, consultants, study staff, and applicable independent ethics committees or institutional review 
boards. The contents of this document shall not be disclosed to others without written authorization from 
WCM.  
 
  
IRB Protocol #: 19-04020045  Version Date:  11/13/[ADDRESS_957344]  
PHI Protected Health Information  
PI [INVESTIGATOR_704530] #: 19-04020045  Version Date: 0 2/23/202 4   
1 1. Protocol Summary  
 
Full Title:      A randomized, placebo -controlled clinical trial examining the efficacy of 
Fecal Microbiota Transplantation (FMT) and subsequent dietary fiber in 
patients with moderate ulcerative Colitis  
Short Title:      MINDFUL   
Clinical Phase:     II  
Principal Investigator:    [INVESTIGATOR_704528], MD PhD  
Study Description:   A double -blind, randomized, placebo -controlled clinical trial examining  
the efficacy and safety of Fecal Microbiota Transplantation (FMT)  and 
high fiber supplementation in patients with active mild to moderate 
Ulcerative Colitis (UC). All enrolled subjects will provide serological, stool 
and mucosal specimen  at each clinic visit  to help further define the 
alterations in microbial profiles and immune cell function in response to 
psyllium fiber after  FMT treatment.   
Sample Size:   N=135,  45 subjects per study arm  
Enrollment:   This study will enroll [ADDRESS_957345] s and screen up to 150 subjects .   
Study Population:   All m ale and female participants at least [ADDRESS_957346] of 
care colonoscopy to assess active disease for study eligibility .  
Enrollment Period:   2019 -2023   
Study Design:   This is a randomized, double -blind, pla cebo -controlled clinical trial  with 
the following treatment assignments:  
1. Investigational FMP250 (one -time)  at week 0  
a. Subjects in this group will also blindly receive 
placebo FMP250 at week 8 by [CONTACT_704567].  
2. Investigational FMP250 (one -time) at week 0 + Psyllium  fiber  
(2x/day  for 8 weeks ) 
a. Subjects in this group will  also blindly receive 
placebo FMP250 at week 8 by [CONTACT_704567].  
3. Placebo FMP250 (one -time) at week 0 with or without  
Psyllium fiber (2x/day  for 8 weeks )  
a. Subjects in this group  will also blindly receive 
investigational FMP250 at week [ADDRESS_957347] -FMT , and 
IRB Protocol #: 19-04020045  Version Date:  11/13/[ADDRESS_957348] -FMT . Mucosal biopsies will also be taken  during the initial 
colonoscopy at day 0 and during the follow -up flexible sigmoidoscopy at 
week 8.  Subjects randomized into the placebo cohort will receive 
investigational FMP250 and subjects randomized into the investigational 
cohort will receive placebo FMP250 by [CONTACT_704568] 8 clinic visit (after week 8 endpoint data are collected) . All subjects 
will return  4 we eks later at week 12  for a clinic visit . All subjects will be 
contact[CONTACT_51095] -up phone calls every subseq uent 6 months for the 
next year . 
Description of Site(s)  Enrolling  
Participants:                The Jill Roberts Center for Inflammatory Bowel Disease  
Gastroenterology and Hepatology at David H. Koch Center  
Weill Cornell Medicine / [LOCATION_001] Presby[CONTACT_24021][INVESTIGATOR_307]  
[ADDRESS_957349], 9th Floor  
[LOCATION_001], NY [ZIP_CODE]  
Study Duration:   2019 -2023  
Participant Duration:   12 weeks  + 1 year follow up  
Study Drug  Name :   [CONTACT_704632]  (FMP250)  
Intervention Description:  Subject s will receive  up to 250cc of blinded investigational or placebo 
FMP250 delivered by [CONTACT_704569] 0. Placebo treatment 
group will receive investigational  FMP250 while the investigational 
treatment groups will receive placebo FMP250 by [CONTACT_704570] 8.  
 
 
 
 
 
 
 
 
 
  
IRB Protocol #: 19-04020045  Version Date:  11/13/2024    
3 
 1.1 Study Schemati c 
  
  
 

IRB Protocol #: 19-04020045  Version Date:  11/13/2024    
4 
  
 
1.2 Study Objectives  
 
1.2.1  Primary Objective   
 
To assess if a dietary  prebiotic  supplementation (psyllium husk powder ) in addition to FMT  is 
superior to  FMT or prebiotics alone to achieve clinical response  in patient s with  mild to 
moderate Ulcerative Colitis  compared to FMT or prebiotic alone.  
 
1.2.2  Secondary Objective (s)  
 
To assess if a dietary  prebiotic supplementation  in addition to FMT compared to either alone  
is superior in achieving  clinical remission, endoscopic response or endoscopic remission , 
histologic response or remission  rates . 
 
To assess clinical response / remission and endoscopic response and remission of Fecal 
Microbiota Transplantation (FMT) for the manage ment of  active mild to moderate Ulcerative 
Colitis compared to placebo.  
 
1.2.3  Exploratory Objective (s) 
   
To define the microbial determinants of successful microbial manipulation therapy from 
mucosal, blood and stool samples collected at day [ADDRESS_957350] of diet on the clinical and microbiome outcomes of Fecal Microbiota 
Transplantation (FMT) for the manage ment of  active mild to moderate Ulcerative Colitis 
compared to FMT or prebiotic alone.  
 
2. Background  
 
2.1 Ulcerative Colitis  
 
Ulcerative c olitis  (UC) is a type of inflammatory bowel d isease (IBD) characterized by [CONTACT_704571][INVESTIGATOR_704531]. This chronic disease may even 
extend to all divisions of the large intestine and in 95% of its cases it involves the rectum1. The highest 
prevalence of UC is reported in Europe ([ADDRESS_957351]) and North America (286 per 
100,000 in [LOCATION_003])[ADDRESS_957352] limited safety profil es. Steroids are efficient for induction therapy; however, they are 
known to have significant side effects and do not provide benefit for maintenance therapy. 
Immunomodulators, such as azathioprine and [ADDRESS_957353] a significant side 
IRB Protocol #: 19-04020045  Version Date:  11/13/[ADDRESS_957354] profile  and limited efficacy in inducing remission . They increase the risk of lymphoma and other 
malignancies, and may result in bone marrow toxicity and hepatotoxicity4,5. Mainstay of treatment 
for patients with UC who fail 5 -ASA therapy are anti -tumor necrosis factor drugs (anti -TNFs) , anti -
integrin therapy (vedolizumab) and the janus kinase inhibitor tofacitinib , which are often efficacious 
with a clinical response rat e reported to be as high as 70%6. Aside from vedolizumab , the se therapi[INVESTIGATOR_704532]7-9. Furthermore, all have significant cost.  Although there  
are numerous  medications available for the management of  UC, patients commonly become steroid -
dependent and/ or refractory to medical management and eventually require surgery10. Patients with 
poorly controlled UC are often desperate for a different method to control their symptoms due to the 
tremendous pain and suffering, loss of productivity, and disease -associated financial burdens.  
Patients with IBD, including UC, harbor various genetic variants in genes regulating immune system 
functio n11. These variants can increase susceptibility to abnormal immune responses to 
microorganisms within the gut resulting in persistent inflammation and the debilitating inflammation 
of UC. Although the etiology of UC is not well understood, the presence of certa in beneficial bacteria 
can prevent disease in experimental animal models of colitis while the loss of these bacteria or 
overgrowth of other types  can trigger induction of inflammatory responses and debilitating symptoms 
of IBD12. The  vast majority of treatment modalities for UC target host factors of inflammation. Despi[INVESTIGATOR_704533], the therapeutic role for microbial manipulation in active UC i s less well defined. 
Although antibiotics are used in the treatment of infectious complications of UC, their role for 
induction or maintenance therapy is unsupported by [CONTACT_704572]. Therapeutic 
manipulation of intestinal microbiota c an be achieved by [CONTACT_704573] . 
 
2.2 Fecal Microbiota Transplant (FMT)  
 
FMT is an emerging therapy that transfers healthy donor fecal bacteria to patients  suffering from G I 
illnesses  with the goal of  re-establish ing a  healthy intestinal bacterial community  in those patients13. 
FMT has shown to be effective  in the management of variou s diseases, most notably  Clostridium 
difficile infections (CDI). A randomized control tria l from 2013  in the New England Journal of Medicine 
evaluated the use of FMT in  the management of  CDI. The results were promising: an overall cure  of 
15 out of 16 patients ( 94%)14.  
There are [ADDRESS_957355] randomized, placebo controlled clinical trial by [CONTACT_704574]. al,  50 patients with active 
UC (23/25) received FMT (donor stool) or placebo (autologous stool) via nasoduodenal delivery twice 
during the 12 weeks study period15. Analysis  showed 41% vs 25% efficacy with no statistical 
differences be tween the groups15. Moayyedi et  al. enrolled 75 study participants who received donor 
FMT or placebo (water) weekly enemas for 6 weeks16. 24% of patients who received FMT showed 
clinical response compared with 5% in placebo group and the difference between the groups w as 
significant16. Paramsothy et al.’s study  delivered donor FMT or placebo in 85 (42/43) patients via 
colonoscopy followed by 5 times per week enema for 8 weeks17. Primary outcome was reached by 
27% of patients from FMT group compared with 8% in placebo group with significant differences 
between the groups17. These clinical findings indicate that despi[INVESTIGATOR_704534], FMT appears to be safe and effective for induction and remission of UC and can be included 
as an adjunctive therapeutic modality for management of the disease.  
Our collaborative team recently completed a pi[INVESTIGATOR_704535], clinical efficacy, and microbial engraftment of single FMT delive ry by [CONTACT_704575]18. We performed a single -center, prospective, open -label pi[INVESTIGATOR_704536] #: 19-04020045  Version Date:  11/13/2024    
6 
 efficacy of two -donor fecal microbiota preparation (FMP) delivery by [CONTACT_19069]. The primary 
outcome was clinical response at week 4 with secondary endpoints including clinical remission, 
mucosal healing at week 4 and safety profile. Overall, 34 patients were screened, and 20 patients 
were enrolled. Seven patients (35%)  achieved a clinical response ( Mayo score ≥ 3 and a bleeding 
subscore ≤1) by [CONTACT_5875] 4. Three patients (15%) were in clinical remission at week 4 (Mayo score ≤2 and 
no subscore >1), and two of these patients (10%) achieved mucosal healing (endoscopy subscore of 
0). Paired analysis showed a significant improvement in Mayo score (Median decre ase of 1.5, p = 0.03) 
and endoscopic subscore (Median decrease of 0.5, p = 0.002) . 
 
Further m icrobiome analysis revealed that signatures of donor -derived microbiota correlate with 
clinical response18. Taxonomic analysis revealed enrichment of Ruminococcus , Odoribacter , and 
Christensenellaceae  in healthy donors and responders, but absent in patients with active disease. In 
contrast, patients who did not respond to treatment had failed to eradicate Fusobacteria , Finegoldia  
and Collinsella . To determine the fecal microbial composition and function at species/strain level, we 
performed metagen omic sequencing of a complete set of three samples (donor, recipi[INVESTIGATOR_24428], 
recipi[INVESTIGATOR_282251]) from three responder patients, who had met the primary endpoint of our pi[INVESTIGATOR_704537]. Relative abundances of microbial species were determined by [CONTACT_704576]2 and pro tein encoding 
genes profiling were determined by [CONTACT_704577]2 pi[INVESTIGATOR_19189]. Analysis of the previously identified 
transferrable genus of Ruminococcus  revealed, that of the several species and strains present in the 
patient samples, abundance of only Ruminococcus  torques was significantly  enriched in responders . 
Collectively, this data revealed that response to single colonoscopic  delivery correlated with 
engraftment of key species of transferrable bacteria in the responder patients. Further studies are 
required to determine factors that enhance the engraftment of these bacteria and increase the 
efficacy of this therapy.  
 
2.[ADDRESS_957356] pathogens by [CONTACT_704578], 
the antimicrobial peptides responsible for the mucosal layer, and by [CONTACT_704579]19. Butyrate is an inhibitor of nuclear factor NF -κB, 
a transcription factor necessary for the expression of pro -inflammatory proteins20, and an 
immunomodulator of macrophages, den dritic cells (DC), and T cells19. Studies in animal models 
demonstrate that supplemental butyrate upregulates regulatory T cells and ameliorates intestinal 
inflammation22,23. Recent studies evaluated the use of various fiber -based diet s in animal models of 
IBD with indigestible fibers having strongest effect on mucosal i nflammation23-25. These curative 
properties substantiate the potential role of a post -transplant fiber therapy as necessary to prolong 
remission and de -escalate immunosuppressive treatments by [CONTACT_704580].  
Efficacy of dietary fiber for management of IBD has been long investigated using fiber rich diet or fiber 
supplements, largely with variable effects. Several clinical trials have demonstrated the therapeutic 
benefit in UC patients with psyllium having sign ificant effect for maintenance of remission and 
germin ated barley for active UC20. Importantly, none of the studies reported disease exacerbation or 
early relapse in patients with IBD. Therefore, controlled data demonstrating the effect of fiber as a 
prebi otic regulator of engraftment and FMT outcome in UC has yet to be explored.  
IRB Protocol #: 19-04020045  Version Date:  11/13/[ADDRESS_957357] factors 
for the management of symptoms, prevention of relapses, and induction of  remission. Although there 
are numerous medications  available for the management  of UC, patients commonly become steroid -
dependent and/ or refractory to medical management.  FMT is an emerging treatment modality for 
UC.  Although  the clinical efficacy of FMT for UC is variable, our preliminary results suggest that 
response may correlate with the engraftment of key beneficial microbiota18. Therefore,  our study  is 
aimed at determining the role of supplemental  fiber as a mechanism to enhance the efficacy of FMT.  
Results from this study have the potential to offer pi[INVESTIGATOR_704538]. Thi s intervention has the potential to impact FMT in UC and microbial 
manipulation therapy more broadly.  
 
Thus, the overall goal of this study is to test the role of supplemental  psyllium in the clinical outcome 
and microbial engraftment of FMT for ulcerative colitis . 
 
2.4.1  FMP Lower Delivery Microbiota Transplant (FMP250)  
In our previous single -center, prospective, open -label pi[INVESTIGATOR_799], we sourced our two -
donor fecal microbiota preparation (FMP) from OpenBiome and found that FMP deliv ery 
by [CONTACT_704581] a 
therapeutic alternative for UC patients. Therefore, we propose to source OpenBiome’s 
FMT Lower Delivery Microbiota Preparation (FMP250) as the investigational drug in this 
clinical trial.  
2.4.[ADDRESS_957358] on stool composition. Interestingly , 
psyllium has the capacity  to provide regularity benefits by [CONTACT_15781]. It can either 
soften stool or increase bowel movements for constipation but more importantly for this 
study, it is able to harden stool and decreased bowel movements for diarrhea.  
 
Psyllium husk powder will be purchased commercially by [CONTACT_704582], excluding the endoscopic criteria.  
IRB Protocol #: 19-04020045  Version Date:  11/13/2024    
8 
  
2.5  Risk/Benefit Assessment   
  
2.5.1 Known Potential Risks   
 
2.5.1 .1.  FMT -related : (adapted from OpenBiome FMP250 Investigator Brochure  V4.0 ): 
 
The following adverse reactions  have been reported in scientific literature to be 
commonly caused by [CONTACT_704583] [ADDRESS_957359] -procedure : 
• Transient diarrhea, abdominal cramps/discomfort, and nausea  
• Fever, bloating, belching, vomiting, borborygmi  
• Constipation and flatulence  
• Flares in IBD patients  
These symptoms are usually self -limiting and of short duration. They may also 
be attributable to the delivery modality (e.g. colonoscopy or upper 
endoscopy)  or underlying disease.  
  
According to Openbiome  and/or peer -reviewed literature , the following serious 
adverse events are potential  risks that have been observed by [CONTACT_208359] -based 
products (not specifically Openbiome) or included based on biological plausibility : 
1. Infection  
a. Bacterial infections from multi -drug resistant organisms (MDROs) 
(i.e. extended spectrum beta -lactamase (ESBL) -producing 
Enterobacteriaceae, vancomycin -resistant enterococci (VRE), 
carbapenem -resistant Enterobacteriaceae (CRE), and methicillin -
resistant Staphylococcus aureus (MRSA) ) 
b. Shiga Toxin -Producing E. Coli (STEC) Infections  
c.  Enteropathogenic E. Coli (EPEC) Infections  
d. SARS -CoV-2 Infection   
e. Diverticulitis, bacteremia, cytomegalovirus colitis, fever , diarrhea 
encephalophagy and pancytopenia, Influenza B and diarrhea, 
norovirus gastroenteritis  
f. Monkeypox Infection  
2. Aspi[INVESTIGATOR_704539]  
3. GI complications (i.e. diarrhea, abdominal pain, appendicitis, peritonitis, IBD 
flare, and diverticulitis)  
4. Allergy/Anaphylaxis  
5. Autoimmune  disorders  
a. Exacerbation of pre -existing autoimmune conditions  
b. Development of Rheumatoid arthritis, Sjogren’s disease, peripheral 
neuropathy, idiopathic thrombocytopenic purpura  
6. Non-infectious disease transmission (i.e. obesity, metabolic syndrome, 
cardiovascular disease, neurologic disorders, psychiatric conditions and 
malignancy ) 
 
IRB Protocol #: 19-04020045  Version Date:  11/13/2024    
9 
  
[IP_ADDRESS].  Psyllium -related  
 
The FDA {CFR - Code of Federal Regulations Title 2 1} recommends sufficient liquid 
consumption when taking dried psyllium husk to avoid any potential risk for  
choking.  In geriatric patients, some rare  side effects may include  abdominal 
discomfort, nausea, mild abdominal cramps, gripi[INVESTIGATOR_007], and faintness34. 
Additionally, o ur investigators hypothesize that bloating could occur as a side 
effect.  
 
2.5.2 Known Potential Benefits   
 
[IP_ADDRESS].  FMT -related  
Our previous pi[INVESTIGATOR_60090] 35% of subjects clinically responded and 15% went 
into clinical remission when evaluated at the [ADDRESS_957360] -FMT18. Similar  clinical 
trials found improvement in clinical response in subjects treated with FMT when 
compared to the placebo groups15-17. However, w e cannot and do not guarantee 
that subjects  will receive any benefits from this study. We hope the information 
learned from this study will benefit other patients with ulcerative colitis in the 
future.  
 
[IP_ADDRESS].  Psyllium -related  
 
Various d ietary fiber interventions  report  that it may be beneficial for IBD 
patients, however, their  results do not consistently demonstrate alleviation of 
disease activity  and/or inducement of clinical remission31. Therefore , we cannot 
and do not guarantee that subjects  will receive any benefits from psyllium in 
combination with FMP250 . We hope the information learned from this study will 
benefit other patients with ulcerative colitis in the future.  
 
2.5.[ADDRESS_957361] including procedural risk 
associated with colonoscopic delivery, this emerging therapeutic strategy appears to be more 
effective than placebo in inducing clinical remission.  This study will a dditionally assess the use of 
psyllium husk as a prebiotic supplement to enhance the efficacy of FMT.  We do not anticipate 
additional risk associated with psyllium.  
 
A FMT placebo arm with psyllium supplement is required to assess the potential clinical efficacy 
of psyllium alone and to serve as a placebo control for FMT.  The placebo arm is required in order 
to determine the efficacy of FMT  + psyllium over psyllium alone.  However, at the end of the study, 
investigational FMT will be provided for patients in the psyllium + placebo arm.   
 
Importantly , no SAEs have been found in any previous FMT intervention, including our pi[INVESTIGATOR_799], 
to be definitely  attributed to the investigational drug . Therefore , we believe the potential benefit 
IRB Protocol #: 19-04020045  Version Date:  11/13/2024    
10 
 of clinical and endoscopic response or remission from FMT concurrently with psyllium 
supplementation outweighs the risks.  
 
2.6 Correlative Studies Background  
 
Our collaborative team recently completed a pi[INVESTIGATOR_704535], clinical efficacy, and microbial engraftment of single FMT delive ry by [CONTACT_704575]18. We performed a single -center, prospective, open -label pi[INVESTIGATOR_704540] -donor fecal microbiota preparation (FMP) delivery by [CONTACT_19069]. The primary 
outcome was clinical response at week 4 with secondary endpoints including clinical remission, 
mucosal healing at week 4 and safety profile. Overall, 34 patients were screened, and 20 patients 
were enrolled. Seven patients (35%)  achieved a clinical response ( Mayo score ≥ 3 and a bleeding 
subscore ≤1) by [CONTACT_5875] 4. Three patients (15%) were in clinical remission at week 4 (Mayo score ≤2 and 
no subscore >1), and two of these patients (10%) achieved mucosal healing (endoscopy subscore of 
0). Paired analysis showed a significant improvement in Mayo score (Median decre ase of 1.5, p = 0.03) 
and endoscopic subscore (Median decrease of 0.5, p = 0.002) .  The present will test the hypothesis 
that prebiotic supplementation with psyllium will increase that clinical response rate over FMT alone.  
Furthermore, the current study will assess additional impact on clinical and endoscopic remission 
rates as well as placebo FMT.  
 
Further m icrobiome analysis revealed that signatures of donor -derived microbiota correlate with 
clinical response18. Taxonomic analysis revealed enrichment of Ruminococcus , Odoribacter , and 
Christensenellaceae  in healthy donors and responders, but absent in patients with active disease. In 
contrast, patients who did not respond to treatment had failed to eradicate Fusobacteria , Finegoldia  
and Collinsella . To determine the fecal microbial composition and function at species/strain level, we 
performed metagen omic sequencing of a complete set of three samples (donor, recipi[INVESTIGATOR_24428], 
recipi[INVESTIGATOR_282251]) from three responder patients, who had met the primary endpoint of our pi[INVESTIGATOR_704537].  Relative abundances of microbial species were determined by [CONTACT_704576]2 and protein encoding 
genes profiling were determined by [CONTACT_704577]2 pi[INVESTIGATOR_19189]. Analysis of the previously identified 
transferrable genus of Ruminococcus  revealed, that of the several species and strains present in the 
patient samples, abundance of only Ruminococcus  torques was significantly  enriched in responders . 
Collectively, this data revealed that response to single colonoscopic  delivery correlated with 
engraftment of key species of transferrable bacteria in the responder patients. This study will 
therefore evaluate the hypothesis that psyllium prebiotic supplementation will change the species 
engraftment.  
 
3. Study Design  
 
3.1 Overall Design  
 
Hypothesis : A high fiber diet will promote the engraftment of healthy donor microbiota and increase 
the efficacy of FMT in UC patients. If successful, this proposal will help us to define the role for dietary 
fiber supplementation in promoting microbial determinants of  successful FMT and enhance the 
clinical efficacy of FMT for UC.  
Study Phase : II 
Study Design : Double -blinded, randomized, p lacebo -controlled clinical trial  
Study Drug : FMT Lower Delivery Microbiota Preparation (FMP250)  
Study Arms : 
IRB Protocol #: 19-04020045  Version Date:  11/13/2024    
11 
 Group 1:  Investigational FMT  
o Subject will receive investigational FMT once at day [ADDRESS_957362] will receive placebo FMT once at week 8 flexible sigmoidoscopy  
o Observed for 12 weeks  
 
Group 2 : Investigational FMT + psyllium fiber  
o Subject will receive investigational FMT once at day 0 colonoscopy  
o Fiber supplementation of  1 teaspoon  2x/day for [ADDRESS_957363] will receive placebo FMT once at week 8 flexible sigmoidoscopy  
o Observed for 12 weeks  
 
Group 3 : Placebo FMT with or without psyllium fiber  
o Subject will receive placebo FMT once at day 0 colonoscopy  
o Half of subjects will be randomized to receive f iber supplementation of 1 teaspoon  
2x/day for [ADDRESS_957364] will receive investigational  FMT once at week 8 flexible sigmoidoscopy  
o Observed for 12 weeks  
Site:  
Weill Cornell Medical Center / [LOCATION_001] Presby[CONTACT_24021][INVESTIGATOR_307] (Clinical Facility)  
• The Jill Roberts Inflammatory Bowel Disease  Center at David H. Koch Center  
Weill Cornell Medicine  Belfer Research Building (Research Laboratory Facility)  
• The Jill Roberts Institute for  Research in  Inflammatory Bowel Disease  
 
Methods to Minimize Bias : 
1. Randomization Bias  
a. A series of randomized blocks of fixed size will be generated with a 1:1 :[ADDRESS_957365] 
enrollment, there will the same number of subjects assigned to each of the three 
study arms.  Additionally, the specific number of subjects within any randomization 
block (i.e., block size) will be blinded to all investigators to avoid any risk for 
unblinding treatment arms prior to the primary endpoint evaluation . 
2. Unblinding Bias 
a. Clinicians are blinded throughout the study so they  will assess the clinical response at 
week 8 and will be unblinded only once this independent scoring  is completed for all 
135 enrolled subjects . This will reduce the risk of potential bias by [CONTACT_704584] (blinded investigational or placebo FMP250) 
at week [ADDRESS_957366] defined 
diagnostic signatures of microbial profiles associated with inflammatory disease phenotype in humans 
IRB Protocol #: 19-04020045  Version Date:  11/13/2024    
12 
 including rheumatoid arthritis and IBD. Emerging clinical data provides evidence for the clinical 
efficacy of FMT  in patient s with ulcerative colitis (UC).  Preliminary data from our own research 
suggests that engraftment and/or particular microbial species correlate with clinical outcome, 
however the factors that determine microbial e ngraftment are not well defined . Therefore, we 
designed a randomized, double -blind, placebo -controlled study to examine the possibility of 
improving the clinical outcome and mi crobial engraftment of FMP250 by  [CONTACT_704585] . Study  subjects  will be randomized into three groups: (1) 
FMP250+Fiber , (2) FMP250 -Fiber , and (3) PlaceboFMP250  with or without  Fiber. Given that fiber alone 
has not shown significant benefit s previously in many UC studies27, we hypothesize tha t subjects given 
PlaceboFMP250+Fiber  will allow us to assess the placebo rate for FMT ( FMP250 only  vs. 
PlaceboFMP250+Fiber ). Also, considering that we will utilize single donor FMP250 samples, 
comparing subjects given FMP250 only  and FMP250+Fiber  will allow us to scientifically assess primary 
endpoints of the impact of prebiotic supplement on engraftment and efficacy.  PlaceboFMP250 -Fiber 
will remove any risk of unblinding and will maintain the integrity of our double blinded study.  
Additionally, p revious reports have suggested that dietary effects of fiber can have crit ical effects on 
the microbiome28.  Moreover, these effects can, in part, be mediated by [CONTACT_704586] T cell repertoire 
and function29.  These pre -clinical data may have a critical impact on the efficacy of FMT in U C, but 
human data are limited. To address this limitation, we will perform metagenomic sequencing on 
donor and recipi[INVESTIGATOR_704541].  Also, as we have previously done, immune cell characterization will be performed to 
assess the potential impact of fiber on T cell function.  
 
3.[ADDRESS_957367] scheduled 
procedure shown in the Schedule of  Assessments (SoA), Section 6.[ADDRESS_957368] of care colonoscopy to confirm  their eligibility to participate  in this 
study.    
 
4.2 Inclusion Criteria  
1. Male or Female ≥  18 years of age.  
2. Documentation of p rior histor y of mild to moderate UC . 
3. Endoscopy confirmed active  UC ≥ 15 centimeters  at day 0 screening colo noscopy . 
IRB Protocol #: 19-04020045  Version Date:  11/13/2024    
13 
 a. As defined by a total M ayo scoring  of 4-10 with an endoscopic sub -score ≥ 1 and a 
stool frequency or rectal bleeding sub-score of ≥ 1. 
4. Patients must have a descending intact colon.  
5. Patients taking steroid or biologic therapy must be on a stable dose for 4 weeks prior to 
screening and maintained throughout the trial.  
6. Eligible patients willing to undergo serological and fecal screening testing prior to FMT to 
document baseline status:  
a. Urine Testing  
i. Pregnancy test ( women with childbearing potential)  
b. Blood Testing  
i. B-HCG (research purposes)  
ii. CBC, ESR, CRP, and BMP (standard of care)  
iii. HIV, type I and II (standard of care)  
iv. Hepatitis A B C Profile  (standard of care)  
v. RPR (treponema pallidum) (research purposes)  
vi. CMV IgM (standard of care)  
vii. Quantiferon -TB (standard of care)  
c. Stool Testing  
i. Calprotectin (standard of care)  
ii. Clostridium Difficile Toxin PCR (standard of care)  
iii. Ova & parasites (standard of care)  
iv. Gastrointestinal Pathogen PCR Panel (standard of care)  
1. Campby[CONTACT_704587]  
2. Plesiomonas Shigelloides  
3. Salmonella Species  
4. Vibrio  Species  
5. Vibrio  cholerae  
6. Yersinia Enterocolitica  
7. Enteroaggregative  E. coli (EAEC)  
8. Enterpathogenic  E. coli (EPEC)  
9. Enterotoxigenic  E. coli (LT/ST)  
10. Shigalike toxin producing E.coli I (STX/ST2)  
11. Cryptosporidium  
12. Cyclospora caretanensis  
13. Entamoeba Cayetanensis  
14. Giardia  
15. Adenovirus  F 40/41  
16. Astrovirus  
17. Norovirus GI/GII  
18. Rotavirus A  
19. Sapovirus  
20. GID PCR INTERP  
IRB Protocol #: 19-04020045  Version Date:  11/13/[ADDRESS_957369] discontinue anti -rCDI antibiotics (e.g. vancomycin, fidaxomicin)  48 hours prior 
to FMT delivery procedure.   
4.3 Exclusion Criteria   
1. Biopsy proven Crohn’s disease  
2. UC patients with severe disease ( defined as a total mayo score  >10)  
3. Clinical complications requiring emergent management (e.g. stricture, bowel obstruction, 
perforation and/or abscess)  
4. Concurrent C. difficile  or other infections  
5. Primary sclerosing cholangitis  
6. Prior history of FMT  
7. Treatment for malignancy within past 5 years  
8. Active or latent tuberculosis  
9. Clinically meaningful laboratory abnormalities  
a. Hb: < 8 
b. ALT: greater than 3x the ULN (upper limit of normal)  
10. History of anaphylactic reactions to food allergens  or allergy to psyllium husk  
11. Pregnancy or lactation  
12. Probiotic use in the [ADDRESS_957370] any lifestyle consideration s. 
However, a 24 —hour diet recall  will be conducted  during our screening clinic visit (day -28 to -3) with 
a clinical nutritionist /registered dietician  or study physician  at Jill Roberts IBD Center in efforts t o 
accurately  observe  and record  each subject’s daily eating patterns. See Section 6.1. 1. for more details.  
 
4.[ADDRESS_957371] of care colonoscopy. A 
minimal set of screen failure information is required to ensure transparent reporting of screen failure 
participants, to meet the Consolidated Standards of Reporting Trials (CONSORT) publishing 
requirements and to respond to queries from regulatory authorities. Minimal information includes 
demography, screen failure details, eligibility criteria, and any serious adverse event (SAE).  
 
Individuals who do not meet the criteria for participation  in this trial (screen failure)  at the day [ADDRESS_957372] of care colonoscopy  may  be rescreened  at a later time .  
 
4.6 Strategies for Recruitment and Retention  
  
IRB Protocol #: 19-04020045  Version Date:  11/13/2024    
15 
 This clinical trial  will recruit potential participants from the Jill  Roberts Center for Inflammatory Bowel 
Disease and related facilities of [LOCATION_001] Presby[CONTACT_24021][INVESTIGATOR_307]/Weill Cornell Medical Center where 
our investigators are members of the medical staff. The Jill  Roberts Center for IBD is a high -volume 
practice , led by [CONTACT_704588]. Ellen Scherl, with over 4,[ADDRESS_957373] the accrual rate to be  approximately 40 
to 50 subjects per year.  
 
Recruiting  efforts for this study will not target  potential participants based on their gender, race, or 
ethnicity. Recruitment strategies  will include submitting a summary of the study to clinicaltrials.gov  
and to the  Jill Roberts IBD Center Website: https://jillrobertsibdcenter.weillcornell.org/research -and-
clinical -trials/clinical -trials .  
 
Subjects will not be compensated with  financial incentives at any point during  the study . 
 
5. Registration Procedures  
 
5.[ADDRESS_957374] Registration  (WCM only)  
 
Subjects will be registered within the WRG -CT as per the standard operating procedure for Subject 
Registration.  
   
5.[ADDRESS_957375] Registration (Sub -sites)  
 
  Not Applicable.    
 
6. Study Procedures  
 
6.1 Schedule of Assessments  
 
Table 1. Schedule of  trial events  
 Day 
-28 to 
-3 Day 
0 Day 
1 Wk 
2 Wk 
4 Wk 
 6 Wk 
8 Wk 
10 Wk 
12 Off 
Studyd 
Informed consent  X          
Demographics  X          
Medical history  X          
Concurrent med ication  X ------------ ---------------------------------------------------------  ----- X  
Treatment Randomization  X          
Physical exam  X    X  X  X  
Vital signs  + Height + Weight  X    X  X  X  
B-HCG (serum pregnancy t est) 
(research purposes ) X          
IRB Protocol #: 19-04020045  Version Date:  11/13/[ADDRESS_957376]  (standard of 
care  and research purposes)   Xc     X    
CRP: C -Reactive Protein (standard of 
care) X*      X    
ESR: Erythrocyte Sedimentation 
Rate (standard of care)  X*      X    
CBCa (standard of care)  X*      X    
CMPb (standard of care)  X*      X    
Blood: HIV screen (standard of care)  X*          
Blood: Hepatitis A B C Profile  
(standard of care)  X*          
Blood:  RPR ( Treponema 
pallidum ) (research purposes)  X          
Blood: CMV IgM (standard of care)  X*          
Blood: Quantiferon -TB (standard of 
care) X*          
Fecal Calprotectin (standard of care)  X*      X    
Stool: Ova &parasites (standard of 
care) X*          
Stool:  Clostridium Difficile  Toxin 
PCR (standard of care)  X*          
Stool: Gastrointestinal Pathogen 
PCR Panele (standard of care)  X*          
Screening Colonoscopy  (standard of 
care )  X         
Blinded ( Investigational  or 
Placebo ) FMP250  Treatment   X         
Follow -up Flex  sigmoidoscopy 
(standard of care )       X    
Blinded Investigational  FMP250 
(research purposes)        Placebo  
group 
only    
Blinded Placebo  FMP250 (research 
purposes)     
   Investiga
tional 
group 
only     
Mucosal Biopsy Collection (research 
purposes)   X     X    
Blood and Stool Collection 
(research purposes)  X--------- X   X  X   X  
Follow -Up Phone calls  (research 
purposes)    X X  X  X  X 
Diet Recall  with Clinical 
Nutritionist  or study MD (research 
purposes)  X          
Psyllium Fiber Supplements  
(research purposes)  X----------------- ------------ ------------------------ --X 
Adverse event evaluation                X -------------------------- ---------------- ------------------------ ---------- ------ X 
*:     These standard of care laboratory tests must be done during the screening period. However , if the subject 
consents on page [ADDRESS_957377] had them conducted within 2 weeks of signing consent.  
IRB Protocol #: 19-04020045  Version Date:  11/13/2024    
17 
 a: Complete Blood Count (WBC count, RBC count, Hb, Hct, platelet count)  
b:    Comprehensive Metabolic Panel (glucose, calcium, sodium, potassium, CO 2, chloride, BUN, Creatinine)  
c:  Urine  pregnancy test (w omen of childbearing potential) as standard of care for colonoscopy  
d:    Off-study evaluation for the following year.  
e:  Gastrointestinal Pathogen GI Panel ( Campby[CONTACT_704587] , Plesiomonas Shigelloides , Salmonella  
Species , Vibrio  Species, Vibrio  cholerae , Yersinia  Enterocolitica , Enteroaggregative E. coli  (EAEC) , 
Enterpathogenic E. coli  (EPEC) , Enterotoxigenic E. coli  (LT/ST) , Shigalike toxin producing E.coli  I (STX/ST2), 
Cryptosporidium , Cyclospora  caretanensis , Entamoeba  Cayetanensis , Giardia , Adenovirus  F 40/41, Astrovirus , 
Norovirus  GI/GII, Rotavirus  A, Sapovirus , GID PCR INTERP)   
 
6.1.1 Screening Visit  (Days  -28 to -3) 
 
• Informed consent  
• Medical history  
• Medication history  
• Physical exam  
• Blood  Testing  
1. B-HCG (research purposes)   
2. CBC, ESR, CRP,  and C MP (standard of care ) * 
3. HIV, type I and II  (standard of care ) * 
4. Hepatitis A B C Profile  (standard of care ) * 
5. RPR (treponema pallidum)  (research purposes)  
6. CMV IgM  (standard of care ) * 
7. Quantiferon -TB Gold Plus, 1 Tube (standard of care)  * 
• Stool Testing  
1. Calprotectin (standard of care)  * 
2. Clostridium Difficile Toxin PCR (standard of care)  * 
3. Ova & parasites (standard of care)  * 
4. Gastrointestinal Pathogen PCR Panel (standard of care)  * 
▪ Campby[CONTACT_704589]  
▪ Plesiomonas Shigelloides  
▪ Salmonella  Species  
▪ Vibrio  Species  
▪ Vibrio cholerae  
▪ Yersinia Enterocolitica  
▪ Enteroaggregative E. coli  (EAEC)  
▪ Enterpathogenic E . coli (EPEC)  
▪ Enterotoxigenic E. coli  (LT/ST)  
▪ Shigalike toxin producing E.coli I  (STX/ST2)  
▪ Cryptosporidium  
▪ Cyclospora caretanensis  
▪ Entamoeba Cayetanensis  
▪ Giardia  
▪ Adenovirus  F 40/41  
▪ Astrovirus  
▪ Norovirus GI/GII 
▪ Rotavirus  A 
▪ Sapovirus  
IRB Protocol #: 19-04020045  Version Date:  11/13/2024    
18 
 ▪ GID PCR INTERP  
• Treatment Randomization (blinded to clinician and subject)  
1. Fiber treatment groups must receive  psyllium dietary sup plements ( 2 
teaspoons /day) to begin on day -3 
• Diet Recall with Clinical Nutritionist /Registered Dietician or study MD  
1. A subjective  dietary record will be assessed anytime during the screening 
period (day -28 to -3), either by [CONTACT_704590], in conjunction 
with the registered dietitian (RD). This meeting  will aim to capture detailed 
information about food and beverages consumed over a certain (typi[INVESTIGATOR_2855]) 
period of time as an estimate of usual intake. The discussion may begin with 
the RD asking the subject “Could you please walk me through a typi[INVESTIGATOR_704542]? ” The RD may then assess what the subject normally eats on a regular 
weekday, and give them the opportunity to tell them a few different options 
they might have for breakfast, l unch and dinner as well as snacks (if their days 
vary). They may also review what kinds of fruits and vegetables they consume 
most commonly, as well as get a sense of how much added sugar is likely in 
the subject’s diet.  
• Stool and blood samples taken for research purposes  
o This can be collected anytime during the screening period or on the day 
of the screening colonoscopy, prior to blinded FMT treatment, but if the 
subject is randomized to receive psyllium fiber, then this should be 
collected before day -3 when they begin the fiber supplementatio n.  
 
*:     These standard of care laboratory tests must be done during the screening period. 
However , if the subject consents on page [ADDRESS_957378] of 
care  within 2 weeks of signing consent.  
 
6.1.2 Treatment Phase  
     
Eligible subjects will be randomly assigned  to one of the three (Placebo or Investigational 
FMP250 +/ - Psyllium) treatment groups .  A series of randomized blocks of  fixed size will 
be generated with a 1:1 :[ADDRESS_957379] be provided two psyllium bottle s to 
begin consumption 3 days prior the colonoscopy.  
 
 [IP_ADDRESS] Screening Colonoscopy  (Baseline , Week 0  Day 0 ) 
 
• Urine pregnancy te st as standard of care  
• Standard of Care Colonoscopy for diagnostic purposes  
1. Mucosal biopsies taken for diagnostic and research purposes  
• FMT  delivery by [CONTACT_704591] #: 19-04020045  Version Date:  11/13/2024    
19 
 1. If active disease, study physician will blindly administer  placebo or 
investigational FMP250  
• Stool and blood samples taken for research purposes , if not previously collected  
during screening period (days -28 to -3). 
 
  [IP_ADDRESS] Clinic Visit 3  (Week 8 ± 5 day(s))  
 
• Medical history  (AE evaluation)  
• Medication history  
• Physical exam  
• Urine pregnancy te st for research purposes  
• Flexible Sigmoidoscopy for diagnostic  purposes  
1. Mucosal biopsies taken for research purposes  
2. Subjects in placebo group blindly receive investigational  FMP250 .  
3. Subjects in investigational groups blindly receive placebo FMP250  
• Stool and blood samples taken for research purposes  
• Standard of Care Testing  
1. Fecal Calprotectin  
2. Serological CBC, ESR, CRP, and C MP 
 
6.1.3 Follow -up Phase  
 
[IP_ADDRESS] Phone Consults  (+/- 2 days)  
• Day 1  
• Week 2  
• Week 6  
• Week 10  
• Every subsequent 6 months for the next year  
[IP_ADDRESS] Clinic  Visits   
• Visit 2 ( Week 4 ± 3 day(s))  
 
o Medical history (AE evaluation)  
o Medication history  
o Physical exam  
o Stool and blood samples taken for research purposes  
 
• Visit 4  (Week 12 ±  5 day(s))   
 
o Medical history (AE evaluation)  
o Medication history  
o Physical exam  
o Stool and blood samples taken for research purposes  
6.1.4  COVID -19 Study Modifications   
 
IRB Protocol #: 19-04020045  Version Date:  11/13/[ADDRESS_957380] a ‘Fedex clinical 
pak’ prepackaged for exempt human specimen and provided with mailing  instructions  via 
phone . All shippi[INVESTIGATOR_704543]’s accou nt and 
a Fedex pi[INVESTIGATOR_704544]’s home will be arranged to support “social distancing” 
practices.  As per Fedex recommendations, the subject will leave the package on their door 
step to minimize interaction with essential Fedex personnel.  
 
7. Study Intervention  
 
7.1 Study Intervention /Device  Description    
 
7.1.1 Investigational and Placebo FMP250  
The proposed intervention will deliver  250 milliliters  of FMP250  by [CONTACT_704592]250 treatment groups at day 0. The placebo treatment group will instead 
receive the placebo FMP250 by [CONTACT_704593] 0 and then the investigational FMP250 by 
[CONTACT_704594] 8 .  
 
Investigational FMP250 is biologically active human fecal material that is pre-screened, tested, 
quarantined, stored, packaged, and labeled by [CONTACT_90458].  Placebo FMP 250 is a control unit 
made of glycerol, saline, and food dye that is stored, packaged, and labeled identically to the 
investigational FMP250, to ensure blinding during delivery. Weill Cornell Medicine has contracted 
OpenBiome to supply 135 investigational FMP250 and 135 Placebo FMP250 directly to the 
Longman labo ratory at Weill Cornell Medicine over the course of the study .  
 
7.1.2  Psyllium Husk Powder  
All subjects assigned to the fiber treatment arm s will be required to take 1 teaspoon 
(approximately 5 grams) of psyllium  husk powder  twice a  day (morning and night)  for [ADDRESS_957381]  that will be  commercially 
sourced from NOW® Foods  by [CONTACT_704595]. Any of the following 
information provided about their prebiotic product is accessible on their website: 
https://www.nowfoods.com/supplements/psyllium -husk -powder -organic .  
 
7.3 Acquisition and Accountability   
   
Psyllium Ordering and Shippi[INVESTIGATOR_007]  – Investigator -appointed  Weill Cornell research  staff will order  
Psyllium Husk Powder , Organic  12 oz. bottles , Item#  5966, UPC#  733739059666 . This unit size  
IRB Protocol #: 19-04020045  Version Date:  11/13/[ADDRESS_957382] enrollment into the study. The quantity of units will be determined 
by [CONTACT_704596].  
 
Psyllium Inventory Records  – The research coordinator for this study will maintain a careful record of 
the inventory . This included product arrival  dates, expi[INVESTIGATOR_1659], lot numbers,  and each unit’s 
subject assignment on a Psyllium Tracking Log . This form is required by [CONTACT_1622], must be kept in a 
safe place and  filled out for all units in the possession of the investigator and/or appointed staff. An 
example of this form is shown below:  
 
 
 
FMP250 Ordering  and Shippi[INVESTIGATOR_007]  – Investigator -appointed  Weill Cornell research  staff will order units 
of Investigational  or Placebo  FMT  material by [CONTACT_260221] (1) submitting orders via an OpenBiome 
specialized online order form , or (2) placing shipment orders directly via phone calls or emails with 
the OpenBiome Clinical Research Associate assigned to the trial.   
 
OpenBiome Clinical Research Associat es:  
Jonathan Watson  
P. [PHONE_14692] ext. 794  
E. [EMAIL_13485]  Sally Kim   
E. [EMAIL_13486]  
 
The initial shipment will need approximately  4-[ADDRESS_957383]  conducted  at OpenBiome.  
Upon approval, all  subsequent shipments of the study agent will be expected to arrive 5 -7 days after 
the original order is placed.  
 
FMP250  Inventory Records  – Investigator -appointed  Weill Cornell research  staff will maintain a 
careful record of the inventory and disposit ion of all agents received from OpenBiome with the 
Material Tracking Lo g, an example is pi[INVESTIGATOR_547033],  provided with each shipment by [CONTACT_90458] . 
This form should be kept in a safe space and must be filled out for all units. Once completed, it must 
be returned to OpenBiome prior to ordering the next shipment.  
 

IRB Protocol #: 19-04020045  Version Date:  11/13/2024    
21 
  
7.4 Formulation, Appearance, Packaging, and Labeling   
 
7.4.1 Investigational FMP250 Formulation and Appearance  
Investigational FMP250 is 25 grams of  pre-screened and tested human donor s tool diluted and 
homogenize d in 12.5% glycerol and normal saline buffer. The solution is then filtered to 330 
microns and aliquoted directly into sterile 250mL high -density polyethylene bottles .  
Potential OpenBiome donors are extensively screened for eligibility prior to stool collection by 
[CONTACT_704597], a Donor Health Questionnaire (DHQ), an in -person interview, 
and a clinical examination by [CONTACT_704598] . During this eligibility 
screening, OpenBiome evaluates the potential donor’s infectious risk factors, potential 
microbiome -mediated conditions, general health status, in addition to their breastfeeding status 
and risk for pregnancy. If patients have comp leted and satisfied the requirements, OpenBiome 
then requires serological, stool, and nasal swab testing to be conducted .  
There is  an extensive standard operat ing procedure , which can be found in the  OpenBiome  IB, 
that is followed to  ensure production and process controls. Therefore, once these have been 
fulfilled, the filtered stool is aliquoted, labelled, and frozen at -20 and then to -80 degrees Celsius. 
Donor stool is collected at the beginning of  a 60 -day window and is not shipped for clinical use 
until the donor undergoes the screening process again. This secondary screening process requires 
the donor to be cleared by [CONTACT_469286], and their stool to be evaluated by a quality assurance 
officer at the end of the co llection window. Donors satisfying all secondary screening criteria will 
be cleared for  stool  shipment.  
 
7.4.2  Placebo FMP250 Formulation and Appearance  
Placebo FMP250 is  a placebo control unit  made  of a sterile -filtered solution with  12.5% glycerol 
and normal saline buf fer in addition to added brown food dye.  Once the placebo ingredients are 
homogenized, the solution is sterile filtered through a .02um inline filter and aliquoted  directly 
into sterile 250mL high -density polyethylene bottles. Bottles are labelled with a unique identifier 
and stored at -80ºC storage until the placebo lot has passed bioburden testing at which point 
material is released for us e in clinical research trials.  Considering the  placebo product  is masked  
by [CONTACT_704599] , it should be indistinguishable  from the investigational FMP250  by [CONTACT_43463].  
 
7.4.[ADDRESS_957384] is comprised of organic  soluble fiber from powdered psyllium  seed husks. This 
commercially available fiber  supplement is also corn -free, dairy -free, egg -free, gluten -free, sugar -
free, soy -free, nut -free, non -GMO, kosher, low sodium, organic and vegan/vegetarian.  Natural 
color variation  (beige to light brown)  may be different between different units .  
 
7.4.[ADDRESS_957385]  
Cambridge, MA [ZIP_CODE]      Bloomingdale, IL [ZIP_CODE]  
E. [EMAIL_13487]      P. ([PHONE_14693] ) 
P. (617) 575 -2201       
  
IRB Protocol #: 19-04020045  Version Date:  11/13/[ADDRESS_957386]  Labeling and Documentation     
OpenBiome’s IB indicates that each  sample  bottle is labeled with (1) the handling and storage 
warning s, (2) a lot number and (3) the expi[INVESTIGATOR_704545] (pi[INVESTIGATOR_704546]) . The lot number is formatted as XXXX -YYYY -ZZ, where XXXX is the donor 
number, YYYY is the donation number, and ZZ marks the bottle number.  Additionally all donor 
screening results will be provided in the stool shipment.  Released placebo units are affixed with 
the same label as active FMP250 units, though the specialized lot numbers w ill allow for 
differentiation.  
 
 
NOW® Foods  brands  each Psyllium Husk Powder , Organic plastic bottle with the following label. 
The label provides nutritional  facts, suggested usage, ingredients, and a bar code for commercial 
use in addition to other details. The lot number and the expi[INVESTIGATOR_704547] (not pi[INVESTIGATOR_280915]).  
 
 
 
 
7.[ADDRESS_957387] Packaging and Handling  
 
OpenBiome will package investigat ional and placebo FMP250 units in PET Corning b ottles with HDPE 
screw -caps (pi[INVESTIGATOR_280915]) . All units will be shipped  by [CONTACT_704600] a Styrofoam 
cooler with a WarmMarker temperature indicator attached to the lid. Upon arrival to the Longman 
laboratory, the package will be immediately checked for product tampering and temperature  
exposure . Each unit should be sealed and then stored promptly  in a -20 or -80 Celsius degree freezer. 
The seal should not be broken unless the sample is going to be thawed the same day  for delivery . 

IRB Protocol #: 19-04020045  Version Date:  11/13/2024    
23 
  
 
NOW® Foods  packages each Psyllium Husk Powder , Organic  product in a white plastic bottle with a 
sealed cap. The bottle is approximately 6.[ADDRESS_957388] stability is not compromised by  [CONTACT_704601] . 
 
NOW® Foods  recommends their Psyllium Husk Powder, Organic  product be stored in a dry and  cool 
place after opening.  We assume the same is recommended for its storage at WCMC, before its 
distribution  to subjects.  
 
7.[ADDRESS_957389] be thawed prior to use by [CONTACT_7053] : 
i. [ADDRESS_957390] be homogenized by [CONTACT_704602] 10 seconds before delivery  
 

IRB Protocol #: 19-04020045  Version Date:  11/13/[ADDRESS_957391] never be reused or refrozen. It should  be immediately disposed 
according to internal WCMC/NYPH protocol.  
7.[ADDRESS_957392] the night before 
the procedure . Additionally , subjects  will be provided anti -diarrheal agent(s) [ADDRESS_957393] to begin consuming three days prior to the day 0 
colonoscopy. They will be asked to take one teaspoon (approximately 5 grams) of this fiber 
supplement twice a day until their week 8 clinic visit which will be approximately 59 days . The 
twice a day dosage is advised to be taken once in the morning (e.g. breakfast) and once in the 
night (e.g. dinner) to help with subject compliance . 
 
NOW® Foods  recommends a tablespoon of this product to be mixed in at least a cup of liquid to 
avoid the risk of choking.  
 
7.8.3 Dosing Delays/Dose Modifications  
 
Not Applicable.  
 
7.9 General Concomitant Medication and Supportive Care Guidelines  
 
All concomitant medications will be recorded and/or updated on subject medication log throughout 
the course of the study  and saved in subject binder  and REDCap.   
 
7.10 Duration of Therapy and Criteria for Removal from Study  
 
Subjects assigned to the investigational FMP250 treatment groups will receive the FMT once at the 
day 0 colonoscopy  and will subsequently receive the placebo FMP250 at week 8 to minimize 
unblinding bias between FMT treatment arms . Subjects assigned to the placebo FMP250 will also 
IRB Protocol #: 19-04020045  Version Date:  11/13/[ADDRESS_957394]  tolerating  the 
advised psyllium  dose for less than one week will not be consid ered in this intention to treat trial as 
tolerating intervention, however, they will still continue with the FMT intervention . Importantly, 
subjects will be considered evaluable for scientific analysis in the Fiber  + placebo or active  FMT  
treatment group if they take the psyllium dosage  for at least one -week post -FMT procedure up until 
the [ADDRESS_957395] -FMT clinic evaluation.  
 
Study Termination Guidelines: A subject’s follow -up in the study will end after one of the follow ing 
applies:  
o Subject’s voluntary withdrawal  
o Subject lost to follow -up 
o Subject death  
o Completion of all scheduled study follow -up clinical visits and phone calls  
 
7.11  Duration  of Follow Up  
 
Subjects will receive subsequent follow -up phone calls every  6 months for  the following year after 
completion  from study  (in-clinic visits)  or until death, whichever occurs first.  Subject s removed from 
study for unacceptable adverse events will be followed  by [CONTACT_704603] /or principal 
investigator  [INVESTIGATOR_704548].  
 
7.12 Measures to Minimize Bias: Randomization and Blinding   
  
Randomization Bias : 
A series of randomized blocks  of fixed size will be generated with a 1:1 :[ADDRESS_957396] for each subsequently enrolled 
patient (i.e., the statistician will give the list that contains the randomized blocks only to the 
research assistant).  
 
Unblinding Bias : 
Clinicians are blinded while they assess the clinical response at week [ADDRESS_957397] been conducted for all 135 study participants . This will 
reduce the risk of potential bias by [CONTACT_704604] 
(blinded investigational or placebo FMP250) at  week 8 by [CONTACT_704605].  
 
Unblinding in the case of emergency (i.e. anticipated or unanticipated serious adverse event) is 
up to the discretion of the treating physician, particularly if it is medically necessary to know what 
treatment assignment the subject received. However, it is advised that the treating physician 
IRB Protocol #: 19-04020045  Version Date:  11/13/[ADDRESS_957398]’s folder and/or eCRF.  
 
7.13 Study Intervention/Follow -up Compliance  
Adherence to the protocol can be assessed and verified from  logs, such as eligibility checklists and 
standard operating procedures (SOPs), that will be created by [CONTACT_704606] . These logs will be based on the 
schedule of events detailed in Section  6.1, Table 1. to ensure the subject’s compliance and that all 
data collection is successfully completed and reviewed  at each visit . These paper forms  will be stored 
in each sub ject’s study binder.  
 
In our previous pi[INVESTIGATOR_799], we also utilized single colonoscopic delivery of FMP250 and did not 
experience any loss to follow up due to our short -term follow -up clinic evaluation at  [ADDRESS_957399]  attempts 
(either  phone call and/or  e-mail)  by [CONTACT_704607] a lost to follow -up.  
 
In regard to safety -phone calls at 6 -months and 1 -year, subjects will be contact[CONTACT_704608] (either 
phone call and/or e -mail). Should subject fail to answer, the investigator or designee will mail a 
certified letter to the subject’s last known mailing a ddress in order to regain contact.  
 
8. Study Intervention Discontinuation and Participant Discontinuation/Withdrawa l 
 
8.1 Discontinuation of Study Intervention  
 
Discontinuation from receiving FMP250  does not mean discontinuation from the study, and remaining 
study procedures should be completed as indicated by [CONTACT_4690].   If a clinically significant 
finding is identified (including, but not limited to changes from baseline) after enrollment, the 
investigator or qualified designee will determine if any change in participant management is needed. 
Any new clinically relevant f inding will be reported as an adverse event (AE).  Certain AE/SAE s may 
result in a safety review and may cause for the dis continuation of the study intervention. See Section  
15.2.  for details on halting rules.  
 
Discontinuation of Psyllium Husk Powder, Organic  during the approximately eight -week  course  does 
not translate to discontinuation from this study . Any subject  tolerating  the advised psyllium  dose for 
less than one week will not be consid ered as tolerating intervention, however,  they  will still continue 
with the FMT intervention . Therefore, the remaining study procedures should be completed as 
indicated in the study protocol . Further details  on what to do if a subject does not finish the complete 
fiber supplement course can be found in Section 7.10. 
 
The data to be collected at the time of study intervention discontinuation will include the following:  
• Reason for discontinuation (escalation of care, not feeling well, surgery , etc. )  
IRB Protocol #: 19-04020045  Version Date:  11/13/2024    
27 
 • All follow -up evaluations ( AE/SAE reporting via phone calls, clinic visits) detailed in Section 
13.   
8.2 Participant Discontinuation/Withdrawal from the Study  
Subjects  are free to withdraw from participation in the study at any time upon notification . However, 
if a subject decides to stop participating in the study we encourage them to speak with the research 
coordinator or investigator  first.   
 
An investigator may discontinue or withdraw a participant from the study for the following reasons:  
• Pregnancy  
• Significant study intervention non -compliance  
• If any clinical adverse event (AE), laboratory abnormality, or other medical condition or 
situation occurs such that continued participation in the study would not be in the best 
interest of the participant  
• Disease progression which requires discontinuation of the study intervention  
• If the participant meets an exclusion criterion (either newly developed or not previously 
recognized) that precludes further study participation  
• Participant lost to follow -up after several attempts to contact [CONTACT_57418].  
 
Patients withdrawn because of SAEs, AEs or at the discretion of the physician will continue to receive 
treatment in accordance with current standard of care.  Patients having AEs will be monitored with 
relevant clinical assessments, laboratory tests, imaging studies and procedures as determined by [CONTACT_47806].  
The date and reason for participant discontinuation or withdrawal from the study will be recorded on 
an electronic  Case Report Form ( eCRF)  created on REDCap . Subjects who sign the informed consent 
form and are randomized but do not receive the study intervention may be replaced.  Subjects who 
sign the informed consent form, and are randomized and receive the study intervention, and 
subsequently withdraw, or ar e withdrawn or discontinued from the study, will not  be replaced.  
 
8.[ADDRESS_957400] these 
patients to ensure they are receiving appropriate follow up care with documentation of any serious 
adverse effects (SAEs), adverse effects (AE) or changes in medical cond ition (for example, Mayo 
score), diagnoses or medications.  
The following actions must be taken if a participant fails to return to the clinic for a required study 
visit:  
• The site will attempt to contact [CONTACT_704609] 1 week 
and counsel the participant on the importance of maintaining the assigned visit schedule and 
ascertain if the participant wishes to and/or should continue in the study.  
• Before a participant is deemed lost to follow -up, the investigator or designee will make every 
effort to regain contact [CONTACT_6635] (where possible, 3 telephone calls and, if 
necessary, a certified letter to the participant’s last known mailing ad dress or local equivalent 
IRB Protocol #: 19-04020045  Version Date:  11/13/2024    
28 
 methods). These contact [CONTACT_13140]’s medical record 
or study file.  
• Should the participant continue to be unreachable, he or she will be considered to have 
withdrawn from the study with a prima ry reason of lost to follow -up. 
 
9. Correlative/Special Studies   
 
9.1 Laboratory Correlative Studies  
 
9.1.1  Microbiome – Laboratory Correlative Study #1  
 [IP_ADDRESS]  Collection of Specimen(s) :  Fecal  
 [IP_ADDRESS]  Handling of Specimen(s) : Frozen -80C  
 
9.1.2  Lamina propria cells  – Laboratory Correlative Study #2  
 [IP_ADDRESS]  Collection of Specimen(s):  Biopsy  
 [IP_ADDRESS]  Handling of Specimen(s): Collected in PBS, Processed in Longman lab  
 
9.1.3  Peripheral Blood  – Laboratory Correlative Study #3  
 [IP_ADDRESS]  Collection of Specimen(s):  Blood sample  
 [IP_ADDRESS]  Handling of Specimen(s): Processed in Longman lab  
 
9.2 Special Studies  
 
9.2.1  Special Correlative Study #1  
  
 [IP_ADDRESS]  Assessment  
Microbial alterations, transferability and engraftment will be studied by [CONTACT_704610]. Previous studies have used reference genome 
alignments to evaluate microbial engraftment, however this approach does not 
determine ta xonomy at the strain level, and therefore it is less accurate in defining the 
shared microbes between donor and patient. To overcome this issue metagenomics post -
quality control sequences will be profiled using StrainPhlAn pi[INVESTIGATOR_19189]. To determine the 
degree  of the engraftment, we will apply principal coordinates analysis to Bray -curtis 
distances. Wilcoxo n signed -rank ( paired ) statistical test s will be used to evaluate the level 
of microbial similarity (Bray -curtis) between donor, pre -FMT and post -FMT. Given the 
dissimilar microbial composition observed in donor and pre -FMT samples in our 
preliminary data, we propose to use these microbial signa tures to infer the origin of the 
post -FMT microbes. Briefly, bacteria shared among donor and pre -treatment samples will 
be removed from the model and the remained unique strains will be calculated. Machine 
learning models, Random Forest procedure, will be  fitted in R -studio to predict bacterial 
engraftment and their persist ence, as previously described.  
9.2.2  Special Correlative Study #2  
  
 [IP_ADDRESS]  Assessment  
Lamina propria mononuclear cells (LPMCs) are the key effectors within the mucosa.  
Numerous studies have characterized the contribution of bacterial signals to the effector 
functions of LPMCs, but the signatures associated with prebiotic supplementation ar e 
IRB Protocol #: 19-04020045  Version Date:  11/13/[ADDRESS_957401] optimized 
processing and freezing conditions to allow for efficient recovery and immune 
pheno typi[INVESTIGATOR_442313] . These samples will then be used to phenotype innate and 
adaptive lymphocyte effector cell function.  In addition, to profiling CD4+ T cell subsets 
by [CONTACT_704611] (ROR t, T -bet, GATA -3, FoxP3) and intrace llular cytokine 
produc tion (IFN, IL-4, IL -17, IL -22), CD8+ T cells from the lamina propria and intra -
epi[INVESTIGATOR_704549].  
 
10.  Measurement of Effect   
 
10.1 Response Criteria  
  
10.1.1 Primary Endpoint  Assessment s  
[IP_ADDRESS] Mayo Scoring System30  
The Mayo Scoring System will be used for the assessment of ulcerative colitis activity. It 
is a composite score that ranges from 0 -12 based on the following four categories: 
bleeding, stool frequency, physician assessment, and endoscopic findings. A partia l Mayo 
Score ranges from [ADDRESS_957402] -FMT. Clinical response is described as a r eduction of the Mayo 
score by >3 points  and >30% reduction from baseline  with an accompanying decrease in 
the sub -score for rectal bleeding of at least 1 point . Clinical remission will be defined by 
[CONTACT_704612] ≤ 2 without any sub -score >1, and Mayo endoscopic sub -score 0 -1. 
Table 2. Mayo Scoring System for the assessment of ulcerative colitis activity.  
IRB Protocol #: 19-04020045  Version Date:  11/13/2024    
30 
  
 
10.1.2 Secondary Endpoint  Assessment s  
 
10.1 .2.1 Biomarkers  
Blood, stool, and mucosal  samples will be processed and analyzed in the Longman 
Laboratory. The schedule and frequency of these collections are present in the Table of 
Events (Table 1). The total amount of blood collected for biomarker and safety evaluations 
will be specified in t he Informed Consent Form.  
[IP_ADDRESS]  Adverse  Event  Reporting 
See Section 13 for more information on AE and/or SAE reporting for safety evaluation . 
 
10.2 Duration of Response  
 
 Not applicable . 
 
10.3 Progression -Free Survival  
 
Not applicable . 
 
10.4 Other Response Parameters  
 
See Section 12.4  for a description of all other study endpoints . 
 
11. Data Reporting / Regulatory Considerations  
 

IRB Protocol #: 19-04020045  Version Date:  11/13/[ADDRESS_957403] s.  
 
11.1.1  REDCap  
 
REDCap (Research Electronic Data Capture) is a free data management software system that is 
fully supported by [CONTACT_57421] -Cornell Medical Center CTSC.  It is a tool for the creation of 
customized, secure data management systems that include Web -based data -entry forms, 
reporting tools, and a full array of security features including user and group -based  privileges, 
authentication using institution LDAP system, with a full audit trail of data manipulation and 
export procedures.  REDCap is maintained on CTSC -owned servers that are backed up nightly and 
support encrypted (SSL -based) connections.  Nationally, the software is developed, enhanced and 
supported through a multi -institutional consortium led by [CONTACT_57422].  
 
11.[ADDRESS_957404]/Ethics Committee Approval  
 
As required by [CONTACT_427], the Investigator will ensure all legal aspects are covered, and 
approval of the appropriate regulatory bodies obtained, before study initiation.  
Before initiation of the study at each study center, the protocol, the ICF, other written material 
given to the patient s, and any other relevant study documentation will be submitted to the 
appropriate Ethics Committee. Written approval of the study and all relevant study information 
must be obtained before the study center can be initiated or the IP is released to the Inv estigator. 
Any necessary extensions or renewals of IEC/IRB approval must be obtained for changes to the 
study, such as amendments to the protocol, the ICF, or other study documentation. The written 
approval of the IEC/IRB together with the approved ICF mus t be filed in the study files.  
The Investigator will report promptly to the IEC/IRB any new information that may adversely 
affect the safety of the patients or the conduct of the study. The Investigator will submit written 
summaries of the study status to the IEC/IRB as required. On com pletion of the study, the IEC/IRB 
will be notified that the study has ended.  
 
Neither the Investigator nor BMS will modify or alter this protocol without the agreement of the 
other. All agreed protocol amendments will be clearly recorded on a protocol amendment form 
and will be signed and dated by [CONTACT_585588]. All protocol 
amendments will be submitted to the relevant institutional IEC/IRB for approval before 
implementation, as required by [CONTACT_427]. The only exception will be when the 
amendment is necessary to eliminate an immediate hazard to t he trial participants. In this case, 
the necessary action will be taken first, with the relevant protocol amendment following shortly 
thereafter.  
Once protocol amendments or consent form modifications are implemented at the lead site, Weill 
Cornell Medicine, updated documents will be provided to participating sites. Weill Cornell 
Medicine must approve all consent form changes prior to local IRB subm ission.  
IRB Protocol #: 19-04020045  Version Date:  11/13/2024    
32 
 Relevant study documentation will be submitted to the regulatory authorities of the participating 
countries, according to local/national requirements, for review and approval before the beginning 
of the study. On completion of the study, the regulatory aut horities will be notified that the study 
has ended.  
 
11.2.[ADDRESS_957405]’s legally 
authorized representative prior to participating in the research study. S ubjects who agree to 
participate will sign the approved informed consent form and will be provided a copy of the signed 
document.   
 
The initial ICF, any subsequent revised written ICF and any written information provided to the 
subject must approved by [CONTACT_57425]. The ICF will adhere to IRB/IEC requirements, applicable 
laws and regulations.  
 
11.2.[ADDRESS_957406] (FDAMA) and the Food 
and Drug Administration Amendments Act (FDAAA), the Sponsor -Investigator of the trial is solely 
responsible for determining whether the trial and its results are sub ject to the requirements for 
submission to http://www.clinicaltrials.gov . Information posted will allow subjects to identify 
potentially appropriate trials for their disease conditions and pursue participation by [CONTACT_3379] a 
central contact [CONTACT_63455].  
 
11.2.[ADDRESS_957407] 2 years since the discontinuation of clinical development of the IP. In 
addition, all subjects ’ medical records and other source documentation will be kept for the 
maximum time permitted by [CONTACT_5035][INVESTIGATOR_307], institution, or medical practice.    
 
12. Statistical Considerations  
IRB Protocol #: 19-04020045  Version Date:  11/13/2024    
33 
  
12.1 S ample Size and Analysis Plan  
Prior studies and clinical experience involving FMT suggests a 27% response rate from a null rate of 
diet alone at 7%. Based on previous work18, we estimate the effect size of clinical response to 
FMT+fiber in patients with IBD to be approximately double the FMT -alone group  (i.e., 55% vs. 27%, 
respectively) . Recruitment of ~135 subjects with 45 patients per arm was calculated assuming a 55% 
response rate at 8 weeks in the FMT+fiber arm and a 27% response rate at 8 weeks in the FMT -alone 
arm, with approximately 80% power to detect this difference (using a two-sided significance level of 
0.05)31. We will conduct pairwise chi -square analysis between the study arms of interests to directly 
address the primary study objective to detect a difference in clinical response  (i.e. FMT+ fiber versus 
FMT alone). The remaining two pairwise comparisons can be considered as secondary aims and thus 
no multiple comparison adjustment is needed.   
Considering a nalys es will be performed based on intent to treat , any subject in the FMT alone (no 
psyllium) or the FMT with psyllium intervention groups with missing primary endpoint data at week 8 
will be labeled as failed treatment (no change in clinical response from baseline). Therefore, subjects 
with missing data w ill have their baseline Mayo score carried forward to remain the same for the 
week 8 primary endpoint.  For primary efficacy analysis, the populations FMT + psyllium vs. FMT alone 
(no fiber)  will be  compared by [CONTACT_219181] -square test (pair -wise group comparisons will also be 
performed).  Those characteristics found to be clinically different between groups a t baseline using 
significance criteria of p<0.05 or known to be clinically important (e.g., in the event randomization 
provided insufficient balance between groups) will be incorporated into a multivariable logistic 
regression model of clinical response (i.e., binary outcome variable). This will facilitate estimating the 
independent effect of treatment group status on clinical response, after controlling for such factors, 
if any, that may differ between the two study arms at baseline . Sensitivity analyses for the primary 
endpoint will also be performed; in addition to carrying forward the baseline Mayo score for subjects 
with missing data at week 8, the minimum, median, and maximum Mayo score of subjects with 
available data at week 8 wi ll be used (imputed) for subjects with missing data at week 8. Similarly, we 
will also explore multiple imputation techniques under varying assumptions of missingness (e.g., 
miss ing completely at  random and missing at r andom ). These multiple imputation techniques will rely 
on regression models to predict the missingness and missing values, and incorporate  uncertainty 
thro ugh an iterative approach. For dealing with the possibility of data not missing at random, a worst -
case analysis will be explored (i.e., missing data are replaced with the “worst” value under the not 
missing at random [ non-ignorable] assumption).  These sensitivity analyses will allow for an 
assessment of the consistency of the primary endpoint difference between groups under  the varying 
assumptions for missing data at week 8.  
Similar analyses will be conducted for secondary and exploratory  endpoints (i.e., need for escalation, 
clinical remission, etc.). For secondary efficacy and safety analysis, comparison populations include: 
(i) FMT alone (no fiber) vs. placebo FMT alone (no fiber); (ii)  FMT (with or without fiber) vs. placebo 
FMT (with or without fiber); (iii)  placebo FMT with fiber vs. placebo FMT alone (no fiber); (iv)  FMT 
with fiber vs. placebo FMT with fiber. All p -values will be two -sided with statistical significance 
evaluated at the 0.[ADDRESS_957408] will be calculated to assess the precision of the obtained estimates. Secondary analysis 
excluding subjects who discontinued the study treatment for reasons clearly not related to the study 
medications will also be performed.  Treatment groups will be assessed at baseline with primary 
objective crite ria. Balance between treatment groups will be assessed by [CONTACT_704613] -
Wallis tests for continuous variables an d chi -square tests or Fisher’s exact tests for categorical 
variables.  
IRB Protocol #: 19-04020045  Version Date:  11/13/2024    
34 
 12.2 Sample Size/Accrual Rate  
 
We anticipate approximately 150 patients to be screened for inclusion into our study, however, 15 
will likely be screening fai lures or dropouts. Therefore, we propose  a sample size of N=135. We 
anticipate to accrue  approximately 3 0-50 subjects/year over the course of our 4-year  study duration.  
 
12.[ADDRESS_957409]-FMT, as defined by [CONTACT_941] r eduction of the Mayo scoring 
system by >3 points  (+30% reduction)  with an accompanying decrease in the sub -score 
for rectal bleeding of at least 1 point  (Section 10.1. 2.2). 
12.4.[ADDRESS_957410] -FMT, as defined by [CONTACT_704612] ≤ 2 without any sub -
score >[ADDRESS_957411] a 1 -point reduction from baseline or a Mayo endoscopic sub -score of 0  
c. Safety will be assessed by:  
1. Subject mucosal biopsies, stool and blood testing.  
2. Subject symptomatology via medical interview, physical exam, and Mayo 
score and change in standard UC medications.  
3. Number and type of treatment related adverse events  
4. Number and type of disease -related complications such as hospi[INVESTIGATOR_602], 
surgeries and endoscopi[INVESTIGATOR_014], medical complications, and mortality.  
12.4.3  Analysis of Exploratory Endpoints  
1. Alterations in microbial profiles as defined by [CONTACT_704614]  
a. Sample collection  
1. Up to 60cc of the recipi[INVESTIGATOR_704550].  
2. Up to 60cc of recipi[INVESTIGATOR_704551] 4 and 8 weeks of follow 
up (as per protocol).  
3. Samples will be aliquoted and stored at -80C for batched analysis.  
b. Sequencing  
1. Fecal DNA extraction  
1. Fecal DNA will be extracted via phenol chloroformor, a commercially 
available resin binding column.  
2. DNA will be stored at -80C until sequencing.  
3. 16S rRNA amplicon libraries will be prepared for analysis by [CONTACT_704615] 454 high throughput sequencing.  
IRB Protocol #: 19-04020045  Version Date:  11/13/2024    
35 
 4. Genomic DNA libraries will be prepared using Illumina library 
preparation for sequencing on Illumina MiSeq or HiSeq.  
5. Metabolomic analysis by [CONTACT_450]  
6. Microbial strains will be isolated for genomic and functional analysis 
in vitro and in mouse models  
2. Alterations in immune cell function from mucosal biopsies as defined by [CONTACT_704616]  
a. Sample collection: 4 biopsies will be collected into sterile saline for cellular analysis  
b. Biopsy will be removed of IEL fraction with dithiothreitol (DTT) followed by [CONTACT_704617].  
Remaining tissue will be digested with collagenase and DNase and purified over a 
discontinuous percoll gradient to obtained lamina propria mononuclear cells.  
a. Stimulated and unstimulated will be analyzed by [CONTACT_4133], 
transcriptional regulation, and cytokine production (including ELISA, 
cytometric bead array, or Luminex).  
c. Biopsy will be transferred to DNA extraction buffer and mechanically homogenized.  
Total DNA will be extracted by [CONTACT_704618].  16S library preparation 
and sequencing will be performed to determine mucosal associated bacteria  
12.[ADDRESS_957412] s included in the study will be assessed for response to treatment if they meet all 
inclusion and exclusion criteria, and then receive  either placebo or investigational  FMP250 
treatment during the screening colonoscopy .   
 
13. Adverse Event Reporting Requirements   
 
Adverse event (AE) monitoring and reporting is a routine  part of every clinical trial. The investigator will 
be required to provide appropriate information concerning any findings that suggest significant hazards, 
contraindications, side effects, or precautions pertinent to the safe use of the drug or device under 
investigation.  Safety will  be monitored by [CONTACT_214524] s or observed 
by [CONTACT_147157], as well as by [CONTACT_57432], x -rays, 
electrocardiographs, etc.  
 
13.1 Adverse Event Definition  
 
An adverse event (also referr ed to as an adverse experience)  is any untoward medical occurrence in 
a patient or clinical trial subject administered FMT that does not necessarily have to have a causal 
relationship with this treatment. It can be any unfavorable and unintended sign (e.g., an abnormal 
laboratory finding), symptom, or disease temporally associated with the use of a FMT but does not 
IRB Protocol #: 19-04020045  Version Date:  11/13/2024    
36 
 imply any judgment about causality. An adverse even t can arise with any use of FMP250  (e.g., off -
label use, use in combination with another drug) and with any route of administration, formulation, 
or dose, including an overdose.  
  
13.1.1  Investigational Drug, FMP250,  Risks ( Potential  Adverse Events)  
 
There  may be risks  for this therapeutic intervention  which will be discussed with study participant by 
[CONTACT_234376] . Risks from donor stool, such as serious blood -stream infection (rare) or fevers, 
abdominal crampi[INVESTIGATOR_007], bloating, diarrhea, and bloody stool (less likely ). The potential risks associated 
with FMP250 may include but are not limited to the following:  
• Transmission of infectious organisms (bacterial, viral, fungal) contain ed in the stool  
o Multi -Drug Resistant Organisms (MDROs)  
▪ A potential risk of fecal microbiota transplantation (FMT) is the 
transmission of antibiotic -resistant bacteria. These are bacteria that are 
resistant to some antibiotics. These bacteria could be transmitted 
through FMT and could cause serious infection or death.  
▪ The study drug, FMP250, that will be delivered by [CONTACT_704619], a universal stool bank where donors who provide stool for 
FMT undergo regular screening for certain antibiotic -resistant bacteria. 
Each FMT is only made available when these sc reens do not detect 
antibiotic -resistant bacteria in the donor before and after the stool 
donation. Donors also undergo regular clinical assessments for any  risk 
factors associated with carryin g antibiotic -resistant bacteria,  such as 
recent use of antibiot ics, visiting certain healthcare facilities, or certain 
travel activities.  
o Shiga Toxin -Producing E. Coli (STEC) and Enteropathogenic E. Coli (EPEC)  
▪ A potential risk of fecal microbiota transplantation (FMT) is the 
transmission of STEC and EPEC. STEC is a type of E. coli that can produce 
a toxin called Shiga toxin. Shiga toxin can be transmitted through FMT 
and can cause symptoms like abdominal pain, d iarrhea (often bloody), 
vomiting, and mild fever. Most people develop symptoms within [ADDRESS_957413] get better within 5 -7 days. EPEC is 
another type of E. coli that can be transmitted through FMT and is 
generally carried asym ptomatically but can sometimes cause transient 
watery diarrhea, similar to traveler’s diarrhea. Symptoms typi[INVESTIGATOR_704552] a matter of days.  
▪ The study drug, FMP250, that will be delivered by [CONTACT_704619], a universal stool bank where donors who provide stool for 
FMT undergo regular screening for these bacteria. Each FMT is only made 
available to delivery when these stool screeni ngs do not detect EPEC or 
STEC in the donor before and/or after the stool donation.  
o SARS -CoV-2 Infection  
▪ A potential risk of fecal microbiota transplantation (FMT) is the 
transmission of SARS -CoV-2, a novel coronavirus that causes the disease 
COVID -19. Infection with SARS -CoV-2 may be transmitted through stool 
and may cause serious illness or death. It is pos sible for healthy, 
asymptomatic stool donors to potentially be infected with SARS -CoV-2. 
▪ The FMT you will receive is provided by [CONTACT_90458], a universal stool 
IRB Protocol #: 19-04020045  Version Date:  11/13/[ADDRESS_957414] 
looks for the specific genetic material that makes up the virus. If a donor 
tests positive for SARS -CoV-2, OpenBiome destroys any FMT units made 
from that donor in the 4 weeks (28 days) before their positive test result. 
The donor is also disqualified from providing stool donations for at least 
[ADDRESS_957415] has not been performed.  
Though these precautions are taken to minimize the risk of SARS -CoV-2 
transmission via FMT, the scientific and clinical community continues to 
learn more about SARS -CoV-2 and COVID -19. There are limits to the 
detection levels of laboratory tests, including  those for SARS -CoV-2. Even 
with current screening and testing strategies, there may be additional 
risks that are unkn own at this time. Although the donor screening tests 
we perform are likely to prevent you from receiving FMT from a donor 
who is infected with SARS -CoV-2, we cannot be absolutely certain that 
the stool you receive has not been contaminated with the SARS -CoV-2 
virus.  
o Monkeypox Infection  
▪ A potential risk of fecal microbiota transplantation (FMT) is the 
transmission of monkeypox. Infection can cause symptoms including 
rash, fever, fatigue, myalgia, and respi[INVESTIGATOR_704553]. Studie s have 
documented the presence of monkeypox virus DNA in rectal swabs 
and/or stool from infected individuals, but it is unknown whether 
monkeypox can be transmitted through stool or from asymptomatic 
infected individuals.  
• Missed polyps, cancer, or other lesion (infusing donor stool interferes with visualization 
of colonic mucosa)  
• Allergic reaction to antigens in donor stool  
IRB Protocol #: 19-04020045  Version Date:  11/13/2024    
38 
 • Enhanced ulcerative colitis activity  
• Theoretical increased risk of developi[INVESTIGATOR_704554] (i.e. obesity, metabolic syndrome , autoimmune conditions, allergic/atopic 
disorders, neurologic disorders, and/ or malignancy)  
 
Many side effects go away shortly after the stool transplant is stopped, but in some cases side effects 
can be serious, long lasting or permanent. In reported experiments of subjects treated with FMT 
via colonoscopy no adverse effects were noted.   
 
13.1.2  FMT Procedural Risks (Potential Adverse Events)  
 
Based on the existing literature and the investigator’s previous experience, the risks from FMT 
and dietary supplement ingestion are low. The usual risks of performing colonoscopy and flexible 
sigmoidoscopy still apply, as well as the minor risk associated with additional tissue biopsy 
procurement during flexible sigmoidoscopy and colonoscopy.  These procedures are overall safe 
with few complications . Risks and side effects related to the delivery procedure  include:  
1. The risks of standard lavage include dehydration and minor electrolyte imbalances.  
2. Standard colonoscopy and sigmoidoscopy include the risk of bowel perforation, bleeding, 
and adverse cardiopulmonary events related to sedation. (serious but less likely)  
3. Many adverse effects of colonoscopy and sigmoidoscopy resolve shortly after the 
procedure has been completed, but in some cases abdominal discomfort and gaseous 
pain can persist for several hours. (common but mild)  
4. Risks related to sedation. (less likely)  
There may also be unpredictable side effects, other than listed above that. Other drugs may be given 
to make side effects that occur less serious and less uncomfortable.  
 
13.1.3  Risk from colonoscopy and sigmoidoscopy  (Potential Adverse Events)  
 
Risks from  colonoscopy and sigmoidoscopy include  perforation (serious but less likely), abdominal 
discomfort during or after the procedure (common but mild), and risks related to sedation (less 
likely). The incidence of risk associated with biopsies taken as standard of care does not increase 
with addit ional biopsies taken for research. These risks include bleeding, intestinal perforation, 
and / or infection. Bleeding associated with biopsy generally resolves spontaneously, however, in 
the unlikely event of persistent bleeding, clips and / or cautery can  be applied to stop the bleeding.  
 
13.1.[ADDRESS_957416] Review (Potential Adverse Events)  
 
Subjects will be asked about their medical history, usage of birth control, concurrent medication. 
There is a risk associated with the loss of privacy or confidentiality due to the probing of 
information. For example, if your identity as a participant in t his study or your identifiable health 
information were disclosed to unauthorized persons, there is the possible risk of discrimination 
by [CONTACT_704620].  
 
13.1.5  Risk from Blood Draws (Potential Adverse Events)  
 
Drawing blood from a vein may cause local pain, bruising, occasional lightheadedness, fainting, 
and very  rarely, infection at the site of the blood draw. Rarely, blood clots may form and infections 
IRB Protocol #: 19-04020045  Version Date:  11/13/[ADDRESS_957417] any of these problems.  
 
13.1.6  Risk from Placebo  (Potential Adverse Events)  
 
In this research study, you may receive a placebo (inactive substance). If you receive the 
placebo, your condition may not change or may worsen.  
 
13.1.7  Risk from Psyllium Husk  (Potential Adverse Events)  
 
The main concern with psyllium husk is the risk of choking, specifically if the product is not 
consumed with sufficient liquid. Our research physicians also hypothesize bloating may occur. The 
following rare side effects may be of concern for older adults: abdominal discomfort, nausea, mild 
abdominal cramps, gripi[INVESTIGATOR_007], and faintness.  
 
 13.1.8  Risk from Anti -Diarrheal Agents  (Potential Adverse Events)  
 
Healthy adults usually don’t experience side effects from antidiarrheal medicines. But side effects 
may be a concern if you are older or have health problems. Side effects of diphenoxylate/atropi[INVESTIGATOR_704555]: drowsiness, dizziness, headache, tiredness, r estlessness, blurred vision, dry mouth, 
nausea, vomi ting, upset stomach, loss of appetite, skin rash, or itching. Unlikely but serious side 
effects of diphenoxylate/atropi[INVESTIGATOR_704556]: stomach or abdominal pain or swelling, severe 
nausea or vomiting, menta l/mood changes (e.g., confusion, depression), or numbness and tingling 
of arms or legs. Side effects of loperamide may include:  dizziness, drowsiness, tiredness, 
constipation, stomach pain, skin rash, or itching. Unlikely but serious side effects may also  include 
severe constipation/nausea/vomiting, stomach or abdominal pain, or uncomfortable fullness of 
the stomach or abdomen.  
 
There may also be side effects, other than listed above that we cannot predict. Other drugs may 
be given to make side effects that occur less serious and less uncomfortable. Many side effects go 
away shortly after the stool transplant is stopped, but in so me cases side effects can be serious, 
long lasting or permanent  
 
13.1. [ADDRESS_957418] -feeding a baby.  
 
What do subjects need to know about reproductive health and/or sexual activity if they are in this 
study?  
 
If a subject is  sexually active, both men and women should use at least one effective 
means  of birth control while participating in this research study. According to the World 
Health Organization and the [LOCATION_002] Center for Disease Control and Prevention, the 
most effective forms of birth control include complete abstinence, surgical sterili zation 
(both male and female), intrauterine devices (IUDs), and the contraceptive implant. The 
next most effective forms of birth control include injectables, oral contraceptive pi[INVESTIGATOR_3353], the 
IRB Protocol #: 19-04020045  Version Date:  11/13/[ADDRESS_957419] effective, methods 
of birth control include male condoms (with or without spermicide) and female condoms.  
 
If a subject  becomes  pregnant while participating in this research study, it is important 
that they  tell the study doctor or other research team member immediately . The subject  
will be required to stop receiving study procedure/intervention  for this study; however, 
other clinical care options will be discussed with them  at that time if necessary  and they 
will continue to complete the AE phone calls, week [ADDRESS_957420] lavage  
3. Less Likely but Serious  
a. Transmission of infection from donor specimen  
b. Allergic reaction to unknown antigen present in donor stool  
c. Risks and side effects related to the colonoscopy or follow -up sigmoidoscopy 
including bleeding, bowel perforation and adverse cardiopulmonary events 
related to sedation  
d. Acquisition of antibiotic resistance or risk factors for chronic diseases such as 
diabetes, inflammatory bowel disease, obesity, or colon cancer  
 
13.1. 11 Adverse Event Characteristics and Related Attributions  
 
CTCAE term (AE description) and grade:  The descriptions and grading scales found in the 
revised NCI Common Terminology Criteria for Adverse Events (CTCAE) version 5 .0 will be utilized 
for AE reporting  in this study  and reported to the primary investigator as frequently as adverse 
events occur.   A copy of the CTCAE version 5 .0 can be downloaded from the CTEP web site 
(http://ctep.cancer.gov ). 
 
• Attribution  of the AE:  
- Definite – The AE is clearly related  to the study treatment.  
- Probable – The AE is likely related to the study treatment.  
- Possible – The AE may be related  to the study treatment.  
IRB Protocol #: 19-04020045  Version Date:  11/13/2024    
41 
 - Unlikely – The AE is doubtfully related to the study treatment.  
- Unrelated – The AE is clearly NOT related  to the study treatment.  
   
13.1. [ADDRESS_957421] ’s medical record and/or  subject  specific AE log.  The AE log will be maintained by [CONTACT_704621] ’s research chart.     
 
13.1.13 Reporting of AE to WCM IRB  
 
All AEs occurring on this study will be reported to the IRB according to the IRB policy, which can 
be accessed via the following link:  
http://researchintegrity.weill.cornell.edu/forms_and_policies/forms/Immediate_Reporting_Poli
cy.pdf .  
 
13.1. 14 Reporting of AE to FDA  
The following AE s will be specifically document ed and reported to FDA  within 15 calendar days  if 
considered unexpected* : 
1. Complications related to the colonoscopy, including sedation, perforation, or bleeding  
2. Complications related to FMT (infection, inflammatory or allergic reactions)  
3. Solicited and u nsolicited AEs  assessed via follow up telephone calls and clinic visits   
4. Development of new symptoms or diagnoses (for example, irritable bowel syndrome, 
inflammatory bowel disease (IBD), autoimmune disorder, neurologic disorder) which may 
be related or unrelated to FMT will be elicited at follow -up calls and visits, documented  
and reported to the FDA  
* According to the FDA, an AE is considered “unexpected” if it is not listed in the investigator 
brochure or is not listed at the specificity or severity that has been observed; or, if an 
investigator brochure is not required or available, is not consistent with the risk information 
described in the  general investigational plan or elsewhere in the current application, as 
amended.  
 
13.1. 15 Reporting Events to Participants  
 
Based on our pi[INVESTIGATOR_704557]’s Brochure by [CONTACT_90458], all anticipated SAEs and 
AEs will be listed  and made known to the subject  in the informed consent. Any additions and/or 
changes  to the list of potential SAEs or AEs will require an update of the informed consent to be 
approved by [CONTACT_1201]. Th erefore, this would require subjects  to be reconsented and made aware 
of any reported events.  
 
13.1.[ADDRESS_957422]’s research binder or medical chart.  
The subject subsequently  will cease further study procedure s (week 8 flexible sigmoidoscopy)  and 
blinded FMT intervention and will only continue to complete the safety follow -ups.  
IRB Protocol #: 19-04020045  Version Date:  11/13/2024    
42 
 13.2 Definition of SAE  
 
Serious adverse events (SAEs) are any adverse experience occurring during or after FMT that results 
in any of the following outcomes: death, life threatening adverse experiences, hospi[INVESTIGATOR_25386], disability or incapacitation, overdose, congenital anomalies and any 
other serious events that may jeopardize the subject or require medical or surgical interv ention to 
prevent one of the outcomes listed in this definition.  
 
13.2.1  Reporting of SAE to IRB  
 
All SAEs occurring on this study will be reported to the IRB according to the IRB policy, which can 
be accessed via the following link:   
http://researchintegrity.weill.cornell.edu/forms_and_policies/forms/Immediate_Reporting_Poli
cy.pdf .  
 
13.2.2  Reporting of SAE to FDA [For Protocols Where WCMC is the Sponsor -Investigator]  
 
IND application sponsor -investigators  must report any suspected adverse reaction or adverse 
reaction to study treatment that is both serious and unexpected. Unexpected fatal or life -
threatening suspected adverse reactions represent especially important safety information and 
must be reported expeditiously by [CONTACT_704622] a written IND safety report 
within  7 calendar days  following the  initial receipt of the information.  Examples of SAE may be 
any of the following:  
i. death,  
ii. a life -threatening adverse event,  
Note : An adverse event or suspected adverse reaction is considered life -threatening if, in the view 
of the investigator or sponsor, its occurrence places the patient or subject at immediate risk of 
death. It does not include an adverse event or suspected adver se reaction that, had it occurred in 
a more severe form, might have caused death.  
iii. in-patient  hospi[INVESTIGATOR_91259] : Adverse events requiring hospi[INVESTIGATOR_208349] 24 hours in duration do not 
meet this criterion. A scheduled hospi[INVESTIGATOR_272] a pre -existing condition that has not worsened 
during participation in the study does not meet this criterion. Pre -planned hospi[INVESTIGATOR_704558]/surgical procedure or routine check -ups do not meet this criterion.  
iv. a persistent or significant incapacity or substantial disruption of the ability to conduct 
normal life functions, or    
v. a congenital anomaly or birth defect . 
 
Important medical events that may not result in death, be life -threatening, or require 
hospi[INVESTIGATOR_708], based upon appropriate medical judgment, they 
may jeopardize the patient or research subject and may require medical or s urgical intervention 
to prevent one of the outcomes listed as serious  
 
Any observation that is also an AE will be recorded in the medical record along with any actions 
taken. If not , all information will be  availabl e at the time of initial report and follow -up SAE reports 
will be completed and submitted.  Anticipated and less serious adverse events will be submitted 
annually in reports to the FDA.  
 
IRB Protocol #: 19-04020045  Version Date:  11/13/2024    
43 
 CDER INDs :  
Food and Drug Administration  
Center for Drug Evaluation and Research  
Therapeutic Biological Products Document Room [ADDRESS_957423] Beltsville, MD [ZIP_CODE] -1266  
 
13.2.3  Reporting of SAE to OpenBiome  
 
OpenB iome requests any and all adverse event reports  to be submitted through their online form: 
www.openbiome.org/adverse -events  at the time of the annual FDA and IRB continuing 
review  submissions . Once the form is submitted, a triage call may be set up with the report’s 
author and a Finch medical professional to assess case s according to FDA ruling. Then, 
Finch/OpenBiome clinical staff may work with WCM clinical/ research staff to determine the next 
steps in the investigation, which may or may not include reporting  a Form FDA 3500. The Clinical 
Safety team at  OpenBiome can also be directly reached at  [EMAIL_13488] or by [CONTACT_1555]  
(617) 575 -2201, option 9 . 
 
13.2.4  Protocol -Specific Exceptions to SAE Reporting  
 
A suspected clinical endpoint event, regardless of when the event occurs, is not to be reported as 
an AE or SAE or reported in an expedited manner as an SAE.  The suspected clinical endpoint event 
includes:  
• Recurrent UC flare  
• Initial response to therapy with initial reduction to Mayo score ≤[ADDRESS_957424] 1 point or an absolute sub -score 
for rectal bleeding of 0 or 1  
 
13.3  AE/SAE Follow Up  
 
All SAEs and AEs reported during this study require the investigator to follow them  until resolution or 
until the investigator confirms that the AE/SAE has stabilized and no more follow -up is required. This 
requirement indicates that follow -up may be required for some events after the subject  discontinues 
participation from the study. Resolution is defined as:  
a. Resolved with or without residual effects  
b. Return to baseline for a pre -existing condition  
c. Fatal outcome; if autopsy is performed, the autopsy report must be provided to the 
sponsor.  
13.4 Time  Period and Frequency for Event Assessment  
 
13.4.1. AE/SAE Monitoring  
 
Each enrolled subject will be monitored for the occurrence of AEs, including SAEs, beginning 
immediately after FMT . The occurrence of an adverse event (AE) or serious adverse event (SAE) 
may come to the attention of study personnel during study visits and interviews of a study 
participant presenting for medical care, or upon review by a study monitor.  Subjects  will be 
questioned at each follow up time -point about unsolicited and solicit ed AE  on stool form and 
frequency, presence of abdominal pain, fevers and subjective well -being and/or examined (at day 
IRB Protocol #: 19-04020045  Version Date:  11/13/[ADDRESS_957425] -FMT via phone call; [ADDRESS_957426] -FMT via office visit  and 
review of patient diary for AE monitoring ) by [CONTACT_704623]. The 
questioning of subjects with regard to unsolicited a dverse events will be generalized such as, 
"How have you been feeling since your last visit?”. The following AEs will be solicited  via phone 
calls and clinic visits  by a study coordinator , along with the intensity of each : 
1. Fever  
a. Mild: Temperature 37.7 -38.6°C  
b. Moderate: Temperature 38.7 -39.3°C  
c. Severe: Temperature 39.4 -40.5°C  
d. Potentially Life Threatening: Temperature >40.5°C  
2. Chills  
a. Mild: No or minimal interference with usual social and functional activities  
b. Moderate: Greater than minimal interference with usual social and functional 
activities  
c. Severe: Inability to perform usual social and functional activities  
3. Fatigue/Malaise  
a. Mild: No or minimal interference with usual social and functional activities  
b. Moderate: Greater than minimal interference with usual social and functional 
activities  
c. Severe: Inability to perform usual social and functional activities  
d. Potentially Life Threatening: Incapacitating fatigue or malaise symptoms 
causing inability to perfume basic self -care functions.  
4. Anorexia (loss of appetite)  
a. Mild: Loss of appetite without decreased oral intake  
b. Moderate: Loss of appetite with decreased oral intake without significant 
weight loss  
c. Severe: Loss of appetite with decreased oral intake associated with significant 
weight loss  
d. Potentially Life Threatening: Life threatening consequences or aggressive 
intervention indicated (TPN or tube feeding)  
5. Abdominal Pain  
a. Mild: Pain causing no or minimal interference with usual social and functional 
activities.  
b. Moderate: Pain causing greater than minimal interference with usual social 
and functional activities.  
c. Severe: Pain causing no inability to perform usual social and functional 
activities.  
d. Potentially Life Threatening: Disabling pain causing inability to perform basic 
self-care functions or hospi[INVESTIGATOR_059] (other than an emergency room visit) 
indicated.  
6. Constipation  
a. Mild: Irregularity of bowel movements not requiring dietary modification, 
laxative or enema.  
b. Moderate: Persistent constipation requiring regular use of dietary 
modifications, laxatives or enemas.  
c. Severe: Obstipation with manual evacuation indicated  
d. Potentially Life Threatening: Life threatening consequences (i.e. obstruction)  
IRB Protocol #: 19-04020045  Version Date:  11/13/2024    
45 
 7. Diarrhea  
a. Mild: Transient or intermittent epi[INVESTIGATOR_704559] ≤3 
stools over baseline per 24 -hour period  
b. Moderate: Persistent epi[INVESTIGATOR_704560] 4 -
6 stools over baseline per 24 -hour period  
c. Severe: Bloody diarrhea OR increase of ≥7 stools per 24 -hour period or IV 
fluid replacement indicated  
d. Potentially Life Threatening: Life threatening consequences (i.e. hypotensive 
shock)  
8. Nausea  
a. Mild: Transient (<24 hours) or intermittent nausea with no or minimal 
interference with oral intake.  
b. Moderate: Persistent nausea resulting in decreased oral intake for 24 -48 
hours  
c. Severe: Persistent nausea resulting in minimal oral intake for >48 hours or 
aggressive rehydration indicated (IV fluids).  
d. Potentially Life Threatening: Life threatening consequences (i.e. hypotensive 
shock)  
9. Vomiting  
a. Mild: Transient or intermittent vomiting with no or minimal interference with 
oral intake.  
b. Moderate: Frequent epi[INVESTIGATOR_704561].  
c. Severe: Persistent vomiting resulting in orthostatic hypotension or aggressive 
rehydration indicated (IV fluids).  
d. Potentially Life Threatening: Life threatening consequences (i.e. hypotensive 
shock)  
Study coordinators will report any and all AE/SAE to the treating clinician and/or PI [INVESTIGATOR_704562] -up. Additionally, Subjects will also be instructed to contact [CONTACT_704624] -FMT to report symptoms experienced.  
• Patients having AEs will be monitored with relevant clinical assessments and laboratory 
tests, as determined by [CONTACT_1963].  
• AEs, actions taken as a result of AEs, and follow -up results must be recorded in the 
patient’s medical record.    
• In addition, patients will receive a follow up phone call [ADDRESS_957427].   
For all SAEs and AEs, relevant clinical assessments and laboratory tests will be repeated as 
clinically appropriate, until final resolution or stabilization of the event(s).  
 
All AEs including local and systemic reactions not meeting the criteria for SAEs will be captured on 
the appropriate electronic case report form (eCRF).  Information to be collected includes event 
description, time of onset, clinician’s assessment of severity, relationship to study product 
(assessed only by [CONTACT_8703] a diagnosis), and time of 
resolution/stabilization of the event. All AEs occurring while on study must be documented 
appropriately regardless of relationship.  All AEs will be followed to adequate resolution.  
 
IRB Protocol #: 19-04020045  Version Date:  11/13/2024    
46 
 Any medical condition that is present at the time that the participant is screened will be 
considered as baseline and not reported as an AE. However, if the study participant’s condition 
deteriorates at any time during the study, it will be recorded as an AE.  
 
Changes in the severity of an AE will be documented to allow an assessment of the duration of 
the event at each level of severity to be performed. AEs characterized as intermittent require 
documentation of onset and duration of each epi[INVESTIGATOR_1865].  
 
Study coordinators  will record all reportable events with start dates occurring any time after 
informed consent is obtained until 7 (for non -serious AEs) or 30 days  (for SAEs) after the last day 
of study participation.  At each study visit, the investigator will inquire about the occurrence of 
AE/SAEs since the last visit.  Events will be followed for outcome information unt il resolution or 
stabilization.  
 
13.4.2 . AE/SAE Assessment  
 
[IP_ADDRESS] Assessment  of Severity  
 
The severity of AEs will be assessed according to the following definitions:  
• Mild : The AE is noticeable to the patient and/or the Investigator but does not 
interfere with routine activity.  
• Moderate : The AE interferes with routine activity but responds to symptomatic 
therapy or rest.  
• Severe : The AE significantly limits the patient’s ability to perform routine activities 
despi[INVESTIGATOR_4795].  
• Life-threatening/disabling: The AE puts patient as risk of death. This does not 
refer to an event that may hypothetically have caused death if it were more 
severe.  
 
13.4.[ADDRESS_957428] assess the relationship of any AE (including SAEs) to FMT, as related 
or not related, based on clinical judgment and using all available information, and may 
include consideration of the following factors:  
a. Possible alternative causes of the AE, including the disease under treatment, pre -
existing conditions, concomitant use of other drugs, and presence of 
environmental or genetic factors.  
b. The temporal association between FMT exposure and onset of the AE.  
c. Whether the manifestations of the AE are consistent with known actions or 
theoretical toxicity of FMT.  
 
The causal relationship between FMT and the AE will be assessed using one of the 
following categories:  
a. Not Related: An AE is not associated with FMT if:  
o An event that can be determined with certainty to have no relationship to the 
FMT.  
o Temporal relationship is lacking (i.e. the event did not occur within a 
reasonable time frame following administration of FMT)  
IRB Protocol #: 19-04020045  Version Date:  11/13/2024    
47 
 o Other causative factors more likely explain the event (i.e. pre -existing 
condition, other concomitant treatments);  
b. Definitely Related:  
o There is a positive temporal relationship (i.e. the event occurred within a 
reasonable time frame following FMT)  
o The AE is more likely explained by [CONTACT_704625]  
o Previously known toxicity of FMT.  
c. Probably Related:  
o  There is a positive temporal relationship (i.e. the event occurred within a 
reasonable time frame following FMT)  
o The AE is more likely explained by [CONTACT_704625]  
o Unlikely to be explained by [CONTACT_4676]’s clinical state or other intervention.  
d. Possibly Related:  
o There is a positive temporal relationship (i.e. the event occurred within a 
reasonable time frame following FMT)  
o Event follows an expected response pattern to FMT, but event could have 
occurred secondary to a number of other factors.  
 
14. Unanticipated Problems  Involving Risks to Subjects or Others  
 
14.1 Definition of Unanticipated Problems Involving Risks to Subjects or Others (UPI[INVESTIGATOR_14845])  
 
The Office for Human Research Protections ( OHRP) considers unanticipated problems involving risks 
to participants or others to include, in general, any incident, experience, or outcome that meets all of 
the following criteria:  
• Unexpected in terms of nature, severity, or frequency given (a) the research procedures that 
are described in the protocol -related documents, such as the Institutional Review Board (IRB) -
approved research protocol and informed consent document; and (b) the  characteristics of 
the participant population being studied;  
• Related or possibly related to participation in the research (“possibly related” means there is 
a reasonable possibility that the incident, experience, or outcome may have been caused by 
[CONTACT_3459]); and  
• Suggests that the research places participants or others at a greater risk of harm (including 
physical, psychological, economic, or social harm) than was previously known or recognized.  
IRB Protocol #: 19-04020045  Version Date:  11/13/2024    
48 
  
 
14.1.2  Unanticipated Problem Reporting  
 
The sub-investigator s will report unanticipated problems ( UPI[INVESTIGATOR_14845] s) to the reviewing 
Institutional Review Board (IRB) and to the lead principal investigator (PI). The UPI[INVESTIGATOR_704563]:  
• Protocol identifying information: protocol title and number, PI’s name, and the IRB 
project number;  
• A detailed description of the event, incident, experience, or outcome;  
• An explanation of the basis for determining that the event, incident, experience, or 
outcome represents an UPI[INVESTIGATOR_14845] ;  
• A description of any changes to the protocol or other corrective actions that have been 
taken or are proposed in response to the UPI[INVESTIGATOR_14845] . 
 
To satisfy the requirement for prompt reporting, UPI[INVESTIGATOR_14845] s will be reported using the following 
timeline:   
• UPI[INVESTIGATOR_14845] s that are serious adverse events (SAEs) will be  reported to the IRB within 1 week  
of the investigator becoming aware of the event.  
• Any other UPI[INVESTIGATOR_704564] 2 weeks of the investigator 
becoming aware of the problem.  
• All UPs should be reported to appropriate institutional officials (as required by [CONTACT_8706]’s written reporting procedures), the supporting agency head (or designee),  
Food and Drug Administration (FDA),  and the Office for Human Research Protections 
(OHRP) within one month  of the IRB’s receipt of the report of the  problem from the 
investigator.  
 
15. Data and Safety Monitoring Plan (DSMP ) 
 
A Weill Cornell Medicine Data Safety Monit oring Board (WCM DSMB) will monitor the data collected in 
this clinical trial  on a quarterly basis  to ensure the safety of enrolled subjects . The first periodic  report to 
the DSMB will be within [ADDRESS_957429] and  will be submitted through the 

IRB Protocol #: 19-04020045  Version Date:  11/13/2024    
49 
 following link: https://research.weill.cornell.edu/integrity -compliance/research -support/human -
research/data -safety -monitoringboard/make -submission . This monitoring plan was chosen for this 
clinical trial because it  will be randomized and is intended  to provide definitive information on the 
effectiveness  and safety of FMTs and fiber supplements in active UC patients.  
 
We will minimize the risk of UC relapse/flare by [CONTACT_704626] .  They  will be encouraged to contact [CONTACT_704627], 
fever or abdominal pain so that further work up can be initiated, and escalation of standard therapy as 
appropriate . Solicited and unsolicited AEs w ill be recorded  at day 1, week 2, week 6, week 10,  week 12, [ADDRESS_957430] any SAEs, new medical 
conditions/diagn oses or changes in medical conditions/medications since last study contact.  If any events 
are noted during these follow -up evaluations, they will promptly be reported and reviewed  by [CONTACT_704628]/or lead PI.  
 
15.1. Plan for informed consent compliance   
 
Written, informed consent will be obtained from each subject prior to the performance of any study 
procedures or assessments. Prior to enrolling a subject into the study, a designated member of the 
study team will explain the study protocol as outlined in the informed consent, procedures and 
objectives to the subject and/or authorized representative. When the subject, or legally authorized 
representative agrees to participation in the clinical trial, he/she or authorized representative must 
understand, sign  and date the IRB approved Informed Consent Document which describes the study 
and potential discomforts, risks and benefits of participating. One copy of the consent form will be 
provided to the subject and one copy will be maintained with the subject's p ermanent medical 
records.  
 
15.[ADDRESS_957431] name [CONTACT_704633]/herself. Written 
consent will be obtained to contact [CONTACT_704629] p urpose of locating the participant for 
follow -up and participants can refuse or revoke such consents. No information about participants will 
be released without their permission or where required by [CONTACT_2371].  
 
15.[ADDRESS_957432] with patients. Both anticipated and 
unanticipated adverse events and problems will be formally monitored and recorded. Unanticipated 
serious adverse events or problems will be reported to the hospi[INVESTIGATOR_704565] (as per local 
reporting requirements), the FDA (within 15 days; or 7 days for unexpected fatal or life -threatening 
events or tran smission of infectious agent). Anticipated and less serious adverse events will be 
submitted annually  in reports to  the FDA .  
 
IRB Protocol #: 19-04020045  Version Date:  11/13/2024    
50 
 The sponsor will provide the following for the annual report under 21 CFR 312.33(b);  
1. Percentage of patients with at least one AE (within pre -specified time periods)  
2. Percentage of patients with at least one SAE (within pre -specified time periods)  
3. Percentage of patients who did/did not experien ce relapse in the [ADDRESS_957433]. Any safety issues will be discussed with the research team and all 
reportable AEs will be communicated to the FDA as detailed above in IND amendment 1 Section 9 and 
12. Specifically if the IND is halted for review, the FDA will be n otified within 2 business days.  Specific 
safety findings will result in temporarily suspending enrollment until a safety review is convened, the 
objective of  which is a decision as to whether the study should continue per protocol, proceed with 
caution, be further investigated, be discontinued, or be modified and then proceed. Suspension of 
enrollment (for a particular group or for the entire study) is another  potential outcome of a safety 
review.  
 
Subsequent review of serious, unexpected, and related AEs by [CONTACT_4318], IRB, the sponsor, or the FDA 
or relevant local regulatory authorities may also result in suspension of further trial 
interventions/administration of FMT at our site. The FDA and study sponsor(s) retain the authority to 
suspend additional enrollment and study interventions/administration of FMT for the entire study, as 
applicable.  Findings that will trigger a safety review are : 
• Death  
• Transmission of an infection from donor to subject via FMT  
• If more than 10% of subjects experience the same Grade 3 Adverse Event  
• If one or more subjects experiences a serious, unexpected adverse event  
• Increased frequency of events (specifically, new diagnoses of inflammatory bowel disease in 
> 2 FMT treated subjects).  
FDA will be notified by [CONTACT_648] , email,  or fax within 48 hours if the study is halted for review.  
 
IRB Protocol #: 19-04020045  Version Date:  11/13/2024    
51 
 References  
 
1. Marie E. Robert, Mark Skacel, Thomas Ullman, Charles N. Bernstein, Kirk Easley, John R. 
Goldblum. Patterns of Colonic Involvement at Initial Presentation in Ulcerative Colitis Am J Clin 
Pathol 2004; 122:94 -99 
2. Siew C Ng, Hai Yun Shi, et al. The Lancet  2017 390, 2769 -2778DOI: (10.1016/S0140 -
6736(17)[ZIP_CODE] -0)  
3. Loftus EV Jr Update on the Incidence and Prevalence of Inflammatory Bowel Disease in the 
[LOCATION_002]. Gastroenterol Hepatol.  2016 Nov;12(11):704 -707.  
4. Imuran (azathioprine). In: Prometheus Laboratories I, ed. accessdata.fda.gov . San Diego, 
[LOCATION_004].May 2011.  
5. Purinethol (mercaptopurine). In: DSM Pharmaceuticals I, ed. accessdata.fda.gov . Greenville, 
North Carolina.April 2011.  
6. Mao EJ,  Hazlewood GS,  Kaplan GG,  Peyrin -Biroulet L,  Ananthakrishnan AN. Systematic review 
with meta -analysis: comparative efficacy of immunosuppressants and biologics for reducing 
hospi[INVESTIGATOR_704566]'s disease and ulcerative colitis. Alime nt Pharmacol 
Ther.  2017 Jan;45(1):3 -13. doi: 10.1111/apt.[ZIP_CODE].  
7. Remicade (infliximab). In: Janssen Biotech I, ed. accessdata.fda.gov. Horsham, 
Pennsylvania  2013.  
8. Cimzia (certolizumab pegol). In: UCB I, ed. accessdata.fda.gov. Smyrna, Georgia .September 
2013.  
9. Humira (adalimumab). In: [COMPANY_013] I, ed. accessdata.fda.gov. North Chicago, Illinois.January 2013.  
10. Asher Kornbluth, MD1, David B. Sachar, MD, MACG1 and The Practice Parameters Committee of 
the American College of Gastroenterology. Ulcerative Colitis in Adults Am J Gastroenterol  2010; 
105:501 –523 
11. Jostins  L, Ripke  S, Weersma  RK, et al. (2012).  Host -microbe  interactions  have  shaped  the genetic  
architecture  of inflammatory  bowel  disease.  Nature. http://doi.org/ 10.1038/nature11582   
12. Gut microbiota in the pathogenesis of inflammatory bowel disease. Atsushi Nishida, Ryo Inoue, 
Osamu Inatomi, Shigeki Bamba, Yuji Naito, Akira Andoh  Clinical Journal of Gastroenterology 
2018, 11 (1): 1 -10 
13. Jeon SR,  Chai J,  Kim C,  Lee CH  Current Evidence for the Management of Inflammatory Bowel 
Diseases Using Fecal Microbiota Transplantation. Current Infectious Disease Reports 2018 May 
26, 20 (8): 21  
14. van Nood E, Vrieze A, Nieuwdorp M, et al. Duodenal infusion of donor feces for recurrent 
Clostridium difficile. N Engl J Med. Jan 2013;368(5):407 -415.  
15. Noortje G. Rossen, Susana Fuentes, Mirjam J. van der Spek, Jan G. Tijssen, Jorn H. A. Hartman, 
Ann Duflou, Mark Löwenberg, Gijs R. van den Brink, Elisabeth M. H. Mathus -Vliegen, Willem M. 
de Vos, Erwin G. Zoetendal, Geert R. D’Haens, and Cyriel Y. Ponsioen . Findings From a 
Randomized Controlled Trial of Fecal Transplantation for Patients With Ulcerative Colitis 
Gastroenterology 2015;149:110 –118 
16. Paul Moayyedi, Michael G. Surette, Peter T. Kim, Josie Libertucci, Melanie Wolfe, Catherine 
Onischi, David Armstrong, John K. Marshall, Zain Kassam, Walter Reinisch, and Christine H. Lee. 
Fecal Microbiota Transplantation Induces Remission in Patients With Active Ulcerative Colitis in 
a Randomized Controlled Trial Gastroenterology 2015;149:102 –109 
17. Paramsothy  S, Paramsothy  R, Rubin DT, Kamm MA, Kaakoush NO, Mitchell HM, Castaño -
Rodríguez N. Faecal Microbiota Transplantation for Inflammatory Bowel Disease: A Systematic 
Review and Meta -analysis.  J Crohns Colitis. [ADDRESS_957434] 1;11(10):1180 -1199  
IRB Protocol #: 19-04020045  Version Date:  11/13/[ADDRESS_957435], Shirley Cohen -Mekelburg, Monica Viladomiu, Gregory G. Putzel, 
Yecheskel Schneider, Fatiha Chabouni, Sarah O'Neil, Brian Bosworth, Viola Woo, Nadim J. Ajami, 
Joseph F. Petrosino, Ylaine Gerardin, Zain Kassam, Mark Smith, Iliyan D. Iliev, Gregory F. 
Sonnenberg, David Artis, Ellen Scherl, Randy S. Longman; Single Delivery of High -Diversity Fecal 
Microbiota Preparation by [CONTACT_704630],  Inflamm atory  Bowel  Diseases , Volume 23, Issue 6, 1 June 2017, Pages 
903–911  
19. João P.B. Silva, Kely C. Navegantes -Lima, Ana L.B. Oliveira, Dávila V.S. Rodrigues, Sílvia L.F. 
Gaspar, Valter V.S. Monteiro, Davi P. Moura and Marta C. Monteiro*, “Protective Mechanisms 
of Butyrate on Inflammatory Bowel Disease”, Current Pharmaceutical De sign (2018) 24: 4154  
20. Bach Knudsen, K.E.; Lærke, H.N.; Hedemann, M.S.; Nielsen, T.S.; Ingerslev, A.K.; Gundelund 
Nielsen, D.S.; Theil, P.K.; Purup, S.; Hald, S.; Schioldan, A.G.; Marco, M.L.; Gregersen, S.; 
Hermansen, K. Impact of Diet -Modulated Butyrate Production on Intestina l Barrier Function and 
Inflammation.  Nutrients  2018 , 10, 1499.  
21. Arpaia N, Campbell C, Fan X et al. Metabolites produced by [CONTACT_704631] T -cell generation. Nature 2013; 504: 451 –455.  
22. Furusawa Y, Obata Y, Fukuda S et al. Commensal microbe -derived butyrate induces the 
differentiation of colonic regulatory T cells. Nature 2013; 504: 446 –450.  
23. S.R. Llewellyn , G.J. Britton , E.J. Contijoch , O.H. Vennaro , A. Mortha, J.F. Colombel, A. Grinspan, 
J.C. Clemente, M. Merad,  J.J. Faith . Interactions between diet and the intestinal microbiota alter 
intestinal permeability and colitis severity in mice. Gastroenterology. 2017 Nov 23. pii: S0016 -
5085(17)[ZIP_CODE] -6. doi: 10.1053/j.gastro.2017.11.030  
24. Ana Letícia Malheiros Silveira, Adaliene Versiani Matos Ferreira, et al.  Preventive rather than 
therapeutic treatment with high fiber diet attenuates clinical and inflammatory markers of acute 
and chronic DSS -induced colitis in mice European Journal of Nutrition 2017, 56 (1): 179 -191 
25. Sonnenburg E.D., Zheng H., Joglekar P., et al: Specificity of polysaccharide use in intestinal 
bacteroides species determines diet -induced microbiota alterations. Cell 2010; 141: pp. [ADDRESS_957436] of viscous soluble fiber on blood pressure: A systematic review and meta -analysis 
of randomized controlled trials.  Nutrition, Metabolism and Cardiovascular Diseases , Volume 28, 
Issue 1, 2018, pp. 3 -13 
27. Linda Wedlake, Natalie Slack, H. Jervoise N. Andreyev, Kevin Whelan; Fiber in the Treatment and 
Maintenance of Inflammatory Bowel Disease: A Systematic Review of Randomized Controlled 
Trials,  Inflammatory  Bowel  Diseases , Volume 20, Issue 3, 1 March 2014, Pages 576 -
586,  https://doi.org/10.1097/01.MIB.[PHONE_14694].[ZIP_CODE].31  
28. Llewellyn SR, Britton GJ, Contijoch EJ, Vennaro OH, Mortha A, Colombel JF, Grinspan A, Clemente 
JC, Merad M, and Faith JJ. Interactions Between Diet and the Intestinal Microbiota Alter Intestinal 
Permeability and Colitis Severity in Mice. Gastroenterology.  2018;154(4):1037 -46 e2.  
29. Chen L, He Z, Iuga AC, Martins Filho SN, Faith JJ, Clemente JC, Deshpande M, Jayaprakash A, 
Colombel JF, Lafaille JJ, et al. Diet Modifies Colonic Microbiota and CD4(+) T -Cell Repertoire to 
Induce Flares of Colitis in Mice With Myeloid -Cell Expression of I nterleukin 23. Gastroenterology.  
2018;155(4):1177 -91 e16.  
30. Rutgeerts P, Sandborn WJ, Feagan BG, et al. Infliximab for induction and maintenance therapy 
for ulcerative colitis. N Engl J Med. Dec 2005;353(23):2462 -2476.  
31. Rosner B.  Fundamentals of Biostatistics . 7th ed. [LOCATION_011], MA: Brooks/Cole; 2011.  
IRB Protocol #: 19-04020045  Version Date:  11/13/2024    
53 
 32. Wong, C., Harris, P. J., & Ferguson, L. R. (2016). Potential Benefits of Dietary Fibre Intervention in 
Inflammatory Bowel Disease.  International journal of molecular sciences , 17(6), 919. 
doi:10.3390/ijms17060919  
33. U.S. Food and Drug Administration (FDA, 2016). "Memorandum to the File: Scientific Review of 
the Beneficial Physiological Effects of Non -Digestible Carbohydrates for Meeting the FDA 
Definition of Dietary Fiber," 2016.  
34. P, Editor(s): Ronald I. Shorr, Angela B. Hoth, Nathan Rawls,  Drugs for the Geriatric Patient,  W.B. 
Saunders,  2007,  Pages 930 -1062 . ISBN 9781416002086. https://doi.org/10.1016/B978 -
141600208 -6.[ZIP_CODE] -X. 
 
 